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Abstract 
The potential toxicity of seven different types of quantum dots without shell (L-cysteine-
CdTe, TGA-CdTe, MPA-CdTe, TGA-CdSe) and with the shell (GSH-CdSe@ZnS, GSH-
CdTe@ZnS,) with different capping agents were evaluated. The growth inhibitory effects of 
the various quantum dots on human pancreatic BON cancerous cells were determined. The 
least cytotoxic of the various quantum dots synthesized and the one displaying the lowest 
growth inhibitory potential and no embryotoxicity was determined to be the GSH-
CdSe@ZnS quantum dots. The GSH-CdSe@ZnS quantum dots were then conjugated to 
gallium, aluminium and indium octacarboxy phthalocyanine and the photophysical behaviour 
of the conjugates studied for potential use in photodynamic therapy and imaging applications. 
The sizes, morphology, thermal stability and confirmation of successful conjugation was 
determined using X-ray diffraction (XRD), transmission electron microscopy (TEM), 
thermogravimetric analysis (TGA) and Fourier transform infrared spectroscopy (FTIR), 
respectively. The study was extended by conjugating amino functionalized magnetic 
nanoparticles (Fe3O4
 
) to indium octacarboxy phthalocyanine to study the photophysical 
behaviour of the conjugate as a potential bi-functional anti-cancer agent (hyperthermia and 
photodynamic therapy applications). A three-in-one multifunctional nanocomposite 
comprising of the quantum dots, magnetic nanoparticles and indium octacarboxy 
phthalocyanine was developed with the aim of developing a multifunctional composite that is 
able detect, monitor and treat cancer. All conjugates showed improved and enhanced 
photophysical behaviour. Finally, GSH-CdSe@ZnS conjugated to aluminium octacarboxy 
phthalocyanine was applied in human pancreatic carcinoid BON cells. The conjugates 
induced cell death dose-dependently. 
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CHAPTER 1 
In this work phthalocyanines are combined with quantum dots and magnetic 
nanoparticles for possible applications in photodynamic therapy (PDT) or 
hyperthermia. Quantum dots are discussed first followed by magnetic nanoparticles 
and phthalocyanines. Finally the possibility of combining all three nanoparticles to form 
a multifunctional three-in-one nanocomposite to be used to detect, monitor and treat 
cancer is presented. 
 
 
 
 
 
 
 
 
2 
 
1. Introduction 
1.1 Basics of Quantum dots 
Quantum dots (QDs) are semiconductor nanoparticles that range from 1 to 10 nm in size. The 
size of the QD is smaller than the Exciton Bohr radius (EBR), thus allowing confinement of 
the excitons in all three dimensions of space [1-5]. QDs have properties that are intermediate 
between bulk materials and individual atoms and molecules. As semiconductors, QDs have 
unique electronic and optical properties [6-11]. They are highly fluorescent with small 
quantum dots emitting at a higher energy than larger quantum dots (Figure 1.1), this makes 
the wavelength of light emitted by the particles tunable.  
 
Figure 1.1: Size dependant fluorescence of quantum dots in aqueous solution [12]. 
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This size tunable absorption and emission property of QDs is extremely useful for biological 
applications; as they can be tuned from the ultraviolet (UV) to the near infrared region (NIR) 
of the spectrum [13-19]. QDs have a characteristic broad absorption and narrow emission 
spectra as shown in Figure 1.2. 
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Figure 1.2: Typical absorbance (a and c) and fluorescence emission (b and d) spectra of 
different sized QDs. Spectra c and d are the larger QDs (unpublished work). 
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1.1.1 Structure of QDs 
QDs are formed from atoms in groups II-VI or III-V of the periodic table. They are made up 
of a metalloid crystalline core, which, depending on its composition and size, will determine 
the fluorescence properties [20]. A bare crystalline core is highly reactive and toxic resulting 
in it being very unstable and also prone to photochemical degradation. The core crystalline 
structure also has surface defects/irregularities which will result in emission irregularities 
such as blinking [21]. The core is composed of materials such as cadmium-sellenide (CdSe) 
and cadmium-telluride (CdTe) (Figure 1.3). Semiconductor shells or coatings are not only 
introduced to stabilize the core, but to further improve optical, physical properties and 
bioavailability of the material and also reduce the toxicity of the core by shielding reactive 
Cd2+and Te2+ ions from being exposed to photo-oxidative environments. Typically, zinc 
sulphide (ZnS) is used as a shell [21].  Additional cappings or coatings with biocompatible 
materials have been introduced to make the QDs soluble in aqueous media and to be non-
toxic. Examples of such coatings include; L
 
-glutathione (GSH), thioglycolic acid (TGA), 3-
mercaptopropionic acid (MPA), polyethylene glycol (PEG) and L-cysteine [22, 23]. The 
coating ligands on the surface of the QDs will also allow coordination to bio-molecules 
(Figure 1. 3).  
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Figure 1.3: Illustration of a core quantum dot encapsulated with ZnS shell and coated 
with a biocompatible material.  
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1.1.2 Synthesis of water soluble QDs  
QDs can be synthesized by either the top-down or bottom-up approach; in this work we used 
the bottom-up approach [24]. For the core (CdSe), this process, known as nucleation involves 
combining cadmium and selenium ions under inert atmosphere. The reaction is allowed to 
reach high temperatures (Oswald ripening) and the core is allowed to grow to a desired size. 
In this work zinc sulphide (ZnS) was used as a shell to coat the core QDs [25]. Application of 
QDs in biological systems is dependent on their solubility. In this work, to render the QDs 
water soluble, GSH was used as a capping agent. This ensured that the photophysical 
properties of the QDs were not altered while providing (-NH2
 
) groups on the surface of the 
QDs that would allow coordination to other biomolecules. In Figure 1.4 the structures of the 
core and core shell QDs capped with water soluble GSH are shown. 
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Figure 1.4: Structures of (a) core CdSe QDs and (b) core shell CdSe@ZnS QDs capped 
with GSH. 
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1.1.3 Quantum dot toxicity 
The use of QDs in clinical applications has been limited by their potential toxicity. When 
introducing QDs in a biological system one needs to take into account the composition, 
toxicity, immunogenicity as well as ADME (absorption, distribution, metabolism and 
excretion) characteristics. The toxicity of the QDs varies, depending on core composition, 
surface coating, surface charge and the size of the QDs [26-28]. There have been very few 
studies designed primarily for toxicological assessment of QDs (i.e dose, duration, frequency 
of exposure and mechanism of action) and as a result there has not been any systematic data 
in literature regarding QDs toxicity [29]. The core of the QDs may contain cadmium (e.g in 
CdSe or CdTe) which is the toxic component. Studies revealed that uncoated QDs were toxic 
at 1µg/ml level concentration in rat pheochromocytoma cells (PC12), which was the same 
toxicity level as cadmium ions (Cd2+
 
) on their own [26]. The study suggests that cadmium is 
released via surface oxidation and that the toxicity is from the core. Studies on human breast 
cancer MCF-7 cells have showed that CdTe@ZnS core shell or core CdTe capped with 
mercaptopropionicacid, cysteamine or n-acetylcysteine significantly reduced the toxicity, 
compared to the bare CdTe core. The presence of ZnS shell eliminated release of cadmium 
ions [30].  
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Tables 1.1 and 1.2 summarize recent work on QD toxicity in vitro and in vivo respectively 
[31-44]. In this work, we determined possible cytotoxic effects of a set of QDs by systematic 
photophysical evaluation in vitro as well as in vivo. QDs were synthesized by the 
hydrothermal aqueous route with sizes in the range of 2.0– 3.5 nm. Cytotoxic effects of QDs 
were studied in the human pancreatic carcinoid BON cell line. As Tables 1.1 and 1.2 show, 
there has been no systematic study where the core or core shell with different coatings have 
been studied using the same cell line. Hence this is the aim of the work. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
10 
 
 
Table 1.1: Summary of QDs toxicity studies in vitro that have been reported in literature. 
QD type Shell Coating agent Biological model 
tested 
Reference 
CdSe 
 
ZnS 
 
DHLA 
 
Dictyostelium 
discoideum and HeLa 
cells 
 
[31] 
 
CdSe 
 
ZnS 
 
None 
 
HeLa cells 
 
 [32] 
CdSe 
 
ZnS 
 
COOH,OH/COOH,OH, 
H2/OH,NH2
 
, CdSe 
MAA,TOPO 
WTK1 cells Primary 
cultures of rat 
hepatocytes 
 
[33] 
CdSe 
 
ZnS 
 
MUA 
 
Vero and HeLa cell 
culture,primary 
cultures of human 
hepatocytes 
 
[28] 
CdSe 
 
ZnS 
 
SSA 
 
EL-4 cells (mouse 
lymphocytes) 
 
[28] 
CdSe 
 
ZnS 
 
PEG Silanized 
 
Human HSF-42 (skin 
fibroblast) & INR-90 
(lung fibroblast) cell 
culture 
[36] 
CdSe 
 
ZnS 
 
Peptide 
 
HEK 239T/17 &COS-
1 (Africangreen 
Monkey) cell lines 
 
[35] 
CdSe 
 
ZnS 
 
Cysteine 
 
MCF-7 (human breast 
cancer) 
[36] 
 
11 
 
CdSe 
 
None None Primary rat  cell 
culture (hippocampal 
neuron) 
[37] 
CdSe 
 
ZnS PEG CaCo-2 (human colon 
carcinoma) cell  
[38] 
CdTe 
 
None  
 
None  
 
Rat pheochromocyto 
ma &murine  
microglial cell line 
 
[27] 
 
CdTe 
 
ZnS 
 
MPA, N-acetyl 
Cysteine 
 
MCF-7 (human breast 
cancer) cell culture 
[39] 
 
CdTe 
 
CdS,CdS/ZnS 
 
None  
 
K562 & HEK 293T 
human cell lines 
[40] 
 
DHLA = dihyrolipoic acid, CdSe = Cadmium selenide, CdTe = Cadmium telluride, TOPO = Trioctylphosphine oxide, MUA = 
Mercaptoundecanoic acid, SSA = Sheep serum albumin, PEG = polyethylene glycol, MTT = 3-(4, 5 dimethylthiazol-2-yl), 2, 5 
dimethyl tetrazolium bromide, IVD = intravenously delivered, ZnS = Zinc sulphide, MPA = 3-mercaptopropionic acid 
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Table 1.2: Summary of QDs toxicity studies in vivo reported in literature. 
QD type 
 
Shell Coating agent Biological model 
tested 
Reference 
InAs ZnS DHLA/PEG Subcutaneously & IV 
injected into rats & 
mice. 
[41] 
CdSe ZnS 
 
MUA/targeting 
Peptides, PEG 
 
IVD into the tail of 
mouse. 
 
[41] 
 
CdSe ZnS 
 
LM, BSA 
 
Intravenously injected 
into the rat. 
 
[42] 
 
CdSe CdS PEG Intradermal injection 
into the mouse. 
[43] 
CdTe ZnS 
 
Monoclonal antibody 
for lung 
IVD into the mouse. [44] 
 
DHLA = dihyrolipoic acid, CdSe = Cadmium sellenide, CdTe = Cadmium telluride, TOPO = Trioctylphosphine oxide, MUA = 
Mercaptoundecanoic acid, PEG = polyethylene glycol, IVD = intravenously delivered, ZnS = Zinc sulfide 
 
 
 
 
 
 
 
 
 
 
1.1.4 Applications 
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The unique properties of QDs have allowed them to be used in various fields especially in 
fluorescence imaging.  Table 1.3 summarizes the properties of QDs that make them superior 
to traditional organic dyes in imaging [45-47]. It is as a result of these properties that QDs 
have been used in industrial and biological applications. Some examples of QDs being used 
in industrial applications include; in opto-electronics, electronics, data storage devices, 
photovoltaics and as photodetectors [48-54]. In biological applications, QDs are used as drug 
carriers, in bio-imaging (in vivo and in vitro), labeling, drug delivery, and photodynamic 
therapy (PDT) and pathogen toxin detection [48, 55, 56].  
In this work we use QDs in photodynamic therapy (PDT) applications. PDT is a form of 
therapy that involves administrating a tumor localizing photosensitizing agent  e.g a 
phthalocyanine, (Pc) followed by irradiation with light of appropriate wavelength (Figure 
1.5) [57]. This results in the generation of cytotoxic singlet oxygen (1O2) by the photoexcited 
photosensitizer [58-61]. The use of QDs-Pc conjugates for PDT applications was first 
reported in 2003 [62]. QDs can be used in PDT either indirectly by transferring energy to a 
photosensitizer through Förster resonance energy transfer (FRET) mechanism (discussed 
below) (Figure 1.6), or directly as they react with molecular oxygen to generate reactive 
oxygen species (ROS) through triplet energy transfer (TET) (Figure 1.7). QDs generate 
singlet oxygen (1O2) with yields of 5% for CdSe [61] and 28% for coreshells [63].QDs can 
also enhance PDT activity of Pcs via the heavy atom effect, which is the enhancement of the 
rate of a spin-forbidden process by the presence of an atom of high atomic number. 
 
In addition they can be used for imaging in PDT. Their photostability, high molar extinction 
coefficient, tunability of emission spectra and high photoluminescence quantum yields have 
made them ideal donors for FRET. In addition, the functionalization of the surface of QDs 
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also allows solubility, biocompatibility and localization of the QDs-Pc conjugate to a specific 
target site [63]. 
Table 1. 3: Table summarizing the advantages QDs have over traditional dyes. 
Properties  Traditional organic dyes Quantum dots 
Emission spectrum Asymmetrical and broad Symmetrical and narrow 
Excitation spectrum Narrow Broad 
Photobleaching threshold Low High 
Absorbance cross section Low High 
Saturation intensity Low High 
Quantum yield Low High 
Decay lifetime Fast (<5 ns) Slow (30- 100 ns) 
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Figure 1.5: Schematic representation of Photodynamic therapy (PDT) using 
photosensitizer at specific wavelength, adapted from reference [57]. 
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1.1.5 Förster resonance energy transfer  
Förster resonance energy transfer (FRET) is a photophysical process where an electronically 
excited fluorescent donor molecule transfers its excitation energy non-radiatively to an 
acceptor molecule in a way that the excited state lifetime of the donor decreases and the 
acceptor is raised to higher energy states as illustrated in Figure 1.6 [13, 64-66]. For efficient 
FRET to occur a few criteria should be satisfied, these include: (i) the fluorescence emission 
spectrum of the donor molecule must overlap the excitation or absorption spectrum of the 
acceptor chromophore, the degree of this overlap is referred to as spectral overlap integral 
(J),(ii) the donor and the acceptor should be in close proximity (1-10 nm) and (iii) the 
fluorescence lifetime of the donor should be long enough to allow FRET to occur [67-70].  
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Figure 1.6: Schematic representation of Förster resonance energy transfer from donor 
molecules (QDs) to acceptor molecules (MPc). D = donor, A = acceptor, a = absorption, 
e = emission, AE= non-radiative acceptor excitation and ASE= acceptor sensitized 
emission [46]. 
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Figure 1.7: Photodynamic therapy mechanism using QDs-Pc conjugate. Light of specific 
wavelength in the presence of molecular oxygen will generate cytotoxic singlet oxygen; 
alternatively radicals could result in destruction of cancer cells. 
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Energy transfer from QDs to different phthalocyanines have been reported before [14, 15, 63, 
71-78], but most researchers simply mixed the two together. Only a few studies have been 
reported for Pc covalently linked to QDs. Table 1.4 summarizes known QDs-Pc conjugates 
that are covalently linked together found in literature [75-84]. Linking Pc to QDs is preferred 
as this allows the formation of controlled conjugates. The Pcs used in Table 1.4 were not 
soluble in water, (with the exception of ZnTCPc and ZnOCPc), hence are not useful for 
biological applications. The central metal used for the water soluble Pcs was Zn. In this work 
the central metals used include the heavier Ga or In, which will encourage intersystem 
crossing (ISC) to the triplet state and hence improve the photophysical properties of the Pcs. 
Octacarboxyphthalocyanines are also used in this work since they are monomeric, because in 
solution aggregates are photoinactive. 
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Table 1.4: Examples of known pthalocyanines-quantum dot conjugates (linked) that have been 
reported in literature. 
Quantum dots and capping Phthalocyanine complex Reference 
CdTe MPA ZnTAPc 
TmMTAAZnPc 
OmMTAAZnPc 
ZnAPPc 
ZnMAPPc  
ZnttbIPc 
 
[75] 
[78] 
[78] 
[77] 
[78] 
[79] 
 
CdTe TGA NiTAPc 
ZnAPPc 
ClInTAPc 
ZnMAPPc  
[75] 
[77] 
[75] 
[78] 
CdTe L-cysteine ZnAPPc 
ZnMAPPc  
[77] 
[79] 
CdTe@Zns-CALNN  ZnMCsPc 
ZnMPCPc 
 (OH)2GeMCPc 
[82] 
[82] 
[82] 
CdTe@Zns-GSH ZnOCPc 
ZnTCPc 
NiTAPc 
[76] 
[76] 
[83]  
CdSe@ZnS GSH (Cl)AlMAPPc 
NiMMSA Pc 
[84] 
[84] 
TmMTAAZnPc  =  [2, 3-[tetra- (mercaptopropanoic acid phthalocyaninto) zinc (II), OmMTAAZnPc =   2, 3-[octa-(2- mercapto-4-
methyl-5-thiazoleaceticacid phthalocyaninto) zinc (II), ZnAPPc =  zinc aminophenoxy Pc,  ZnMAPPc =  zinc mono amino Pc, 
ZnttbIPc =  tris [9 (10),16 (17),23 (24)-tertbutyl] imidopthalocyanito zinc (II),  ZnTAPc  =  zinc tetra amino Pc,  NiTAPc  =  nickel 
tetra amino Pc,  ClInTAPc  =  chloro indium tetra amino Pc,ZnMCsPc  =  zinc monocysteinyl Pc,   ZnMPCPc = zinc mono phenoxy 
carboxy  Pc,  ZnOCPc = zinc octacarboxy pthalocyanine,  ZnTCPc = zinc tetracarboxy pthalocyanine,  CoTAPc = cobalt tetra 
amino Pc,  NiMMSA Pc =  nickel monomercaptosuccinic acid phthalocyanine  
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1.2 Magnetic nanoparticles  
Magnetite is mainly composed of iron oxide (Fe3O4) and maghemite (ϒ-Fe3O4
 
). Magnetite 
has a cubic inverse spinel structure [85]. It has a face-centered cubic closed packing formed 
by the oxygen molecules and the Fe cations occupying interstitial tetrahedral or octahedral 
sites [86], as shown in Figure 1.8. Magnetic iron oxide nanoparticles compared to other 
magnetic materials have good chemical stability, magnetic responsiveness and 
biocompatibility [87]. The important properties of magnetic nanoparticles (MNPs) relevant 
for medical applications are: low toxicity, water solubility, injectability and high-level of 
accumulation in target tissue [88-90].  
 
Figure 1.8: Schematic of a partial unit cell and magnetic ordering of spinel ferrite 
structure [85]. A and B are the two cationic sites in the spinel structure through which 
coordination occurs with oxygen. Fe3O4 as spinel ferrite is FeFe2O4 (AB2O4
 
). 
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1.2.1 Synthesis and stabilization 
Magnetic iron oxide nanoparticles (MNPs) can be prepared either in the aqueous or organic 
phase. Typically iron oxide nanoparticles are prepared through bottom-up strategies, such as 
co-precipitation, micro-emulsion, hydrothermal processing and thermal decomposition [85, 
87, 91]. The co-precipitation method is the most commonly used approach due to its 
simplicity and efficiency; hence we make use of the method in this work. The stability of 
MNPs can be improved by grafting of polymers or surfactants on the surface of the 
nanoparticles, forming a layer that will generate an effective repulsive force between the 
nanoparticles and prevent flocculation [92]. The coating on the surface of the nanoparticles 
also prevents aggregation [93]. In this work we use 3-aminopropyltriethoxysilane (APTES) 
as a coating material for MNPs and also take advantage of the –NH2 
 
group on APTES, which 
will form an amide bond with the carboxy substituted phthalocyanine. 
1.2.2 Applications 
MNPs have attracted a lot of attention in various research fields and have great potential in 
magnetic resonance imaging (MRI), drug delivery [93, 94] and hyperthermia (HPT) [46]. In 
hyperthermia, superparamagnetic biocompatible nanoparticles in solution (magnetite) are 
injected into the tumour tissue where they are stimulated by an alternating current (AC) to 
produce heat between 41 0C and 46 0C, leading to tumour cell death [95,96]. Cancer cells are 
hypoxic (poorly oxygenated), compared normal cells which are anoxic (well oxygenated), 
this property makes cancer cells more sensitive to temperatures exceeding 410
 
C compared to 
normal cells [88].  
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The combination of PDT and hyperthermia has advantages including the fact that 
hyperthermia increases the effectiveness of PDT, as higher temperatures will improve blood 
flow to tumors and better blood flow can deliver the drugs to the cancer cells. Also in HPT 
cellular uptake of oxygen in its ground state (heat results in the dilation of cells which allows 
free flow of oxygenated blood to the cells) will increase, which is essential to produce 
cytotoxic derivatives of oxygen in PDT [97, 98].  
 
In this work, we synthesized MNPs and covalently link them to Pc to form a bi-functional 
anticancer agent, with the intention of combining hyperthermia with PDT (Figure 1.9). Pcs 
have been linked to MNPs using ZnPc derivatives in literature [99-101]. This work used 
heavier central metals, Ga and In as central metals. Later in the work we also develop a three-
in-one multifunctional nanocomposite, combining PDT (Pc), hyperthermia (MNPs) and 
fluorescence imaging (QDs).  
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MNPs-Pc 
conjugate
Fluorescence
imaging & MRI
PDT
HPT
Light
Figure 1.9: Schematic representation of therapeutic strategy using combined 
hyperthermia and photodynamic therapy. DDS = Drug delivery system, MI = Magneto 
impedance, MRI = Magnetic resonance imaging, HPT = hyperthermia and PDT = 
photodynamic therapy [98].  
 
 
 
 
 
 
 
25 
 
1.3 Phthalocyanines  
Phthalocyanines are symmetrical, aromatic, macrocyclic compounds which have a 
conjugated system of 18π electrons [102-104]. These molecules have four isoindole groups 
that are linked by four nitrogen atoms, resulting in a closed ring [105], as shown in Figure 
1.10.  
 
 
Figure 1.10: Molecular structure of metallopthalocyanine showing α, β positions and 
isoindol units. 
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Phthalocyanines form stable complexes with many metal ions (over 70 have been reported), 
and many metallophthalocyanines have been prepared by directly chelating metal cations 
with the four central nitrogens of the macrocycle, thus replacing the two central hydrogen 
atoms [102].  Metallating the Pc results in a move from an unmetallated D2h symmetry to a 
metallated D4h symmetry Figure 1.11 [106]. Substituents can be placed on the peripheral and 
non-peripheral positions.  The addition of substituents on the ring enhances the solubility and 
also alters the properties of the Pc [106,107]. Properties such as strong absorption in the red 
region of the spectrum, high thermal and chemical stability, and extinction coefficients of the 
order of 105 M-1 cm-1 
 
[102-108], have led to the use of phthalocyanines in a variety of 
applications.      
 
Figure 1.11: Difference between (a) metallated MPc with D4h symmetry and (b) 
unmetallated MPc with D2h
 
 symmetry.  
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1.3.2 Electronic and absorption properties of Pcs 
Typical absorption spectra of a monomeric Pcs consist of two very distinct bands: a narrow Q 
band around 670 nm and a weaker Soret band (B band) in the UV region around 350 nm, 
Figure 1.12 [99]. The bands are a result of π-π* transitions within the delocalized 18π 
electron system of the ring.  The B band is a result of superimposition of the B1 and B2
 
 
bands. When using transparent solvents, the N, L, C bands can be observed at high energy 
[102]. A charge transfer (CT) band may also be observed for diamagnetic Pcs such as Zn and 
Mg phthalocyanines [107]. 
 
Figure 1.12: Typical ground state absorption spectra of phthalocyanine [99]. 
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1.3.3 Applications 
 Phthalocyanines have found applications in many areas, including their use in molecular 
electronics, semiconductors and photonics [110], as electrocatalysts, in electrochemical 
sensor development [111, 112] and in medicine as photosensitisers in photodynamic therapy 
(PDT) [102]. Of interest in this study is using phthalocyanines in PDT applications.  
Phthalocyanines are used due to the fact that they are able to accumulate in the cancerous 
tissue for a long time and can be engineered to possess necessary energy requirements to 
produce singlet oxygen. 
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1.4 Combining multiple nanoparticles into a single nanosystem  
 The incorporation of diagnostic and therapeutic functions into a single nanoscale system for 
more effective and improved treatment has been of interest recently. Nanoparticles have 
potential as they are able to achieve dual functions if more than one type of nanostructure can 
be incorporated into a nano-assembly, which Sailor and Park [113] referred to as a “hybrid 
nanoparticle”. The hybrid nanoparticle is made up of two or more nanoparticles assembled in 
a functional structure that itself is in nanoscale dimensions [114, 115]. The idea behind the 
development of hybrid nanoparticles is developing nanosystems that have biomedical 
properties that are superior to the individual components of the nanosystem. Another 
advantage is the ability to monitor the distribution of the drugs in the body which allows the 
efficacy and the progress of the therapy to be monitored. 
There have been a few nanosystems developed for the cancer treatment that integrate two or 
more nanocomponents into single nanodevices [116,117]. These systems follow on the 
concept of a “theranostic” device, where both diagnostic and therapeutic functions are 
administered in a single dose [118]. Quantum dots and magnetic nanoparticles have been 
combined with other nanoparticles for possible medical applications [119-122].  
Other nanoparticles such silica and gold have been used as drug carriers and are also 
designed to photothermally destroy the malignant tumour, respectively. Table 1.5 
summarizes examples of nanoparticles used for simultaneous therapeutic detection and 
diagnosis and treatment reported in literature [123-128]. 
Table 1.5 shows that apart from the work reported in reference [128] (in the absence of silica 
encapsulation), there have been no other reports on the type of multi-functional 
nanocomposites presented in this work. 
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Table 1.5: Nanoparticles used for simultaneous diagnostic and therapeutic detection 
and treatment of cancer 
Structural 
component 
(therapeutic) 
Functional 
component 
(diagnostic) 
Target Function Reference 
Multi walled carbon 
nanotubes 
Magnetic nanocrystals Murine renal 
carcinoma cells 
Photothermal therapy 
and MRI 
[123] 
Single walled carbon 
nanotubes 
Quantum dots Head and neck 
squamous carcinoma 
cells and xenografts 
Incorporating 
therapeutic molecule 
cisplatin and optical 
imaging 
[115] 
Multi walled carbon 
nanotubes 
Magnetic nanocrystals BxPC-3 human 
pancreatic cancer cells 
Incorporating 
therapeutic molecule 
gemcitabine and 
magnetic targetting 
[125] 
Gold nanorods Magnetic nanocrystals SK-BR-3breast cancer 
cells 
Photothermal therapy, 
fluorescence imaging 
and MRI 
[126] 
Gold nanoshells Magnetic nanocrystals SK-BR-3breast cancer 
cells 
Photothermal therapy 
and MRI 
[127] 
Phthalocyanine Magnetic 
nanoparticles& 
Quantum dots  
         _ PDT, imaging and 
hyperthermia 
[128] 
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In this work we develop a hybrid nanoparticle that will be used to detect, monitor and treat 
cancer. The hybrid nanoparticle is made up of L-glutathione capped quantum dots (GSH-
CdSe@ZnS), amino functionalized Fe3O4 magnetic nanoparticles (MNPs) and indium 
octacarboxy phthalocyanine (ClInPc(COOH)8 
 
).   
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1.5 Photophysical and photochemical parameters 
1.5.1 Fluorescence quantum yields and lifetimes 
The amount of fluorescence emission from the singlet state is quantified by the fluorescence 
quantum yield (ΦF). Quantum yields are defined as the number of photons taking part in an 
event for every photon absorbed. Therefore the fluorescence quantum yield (ΦF) is defined 
by the number of molecules fluorescing per number of photons absorbed. The fluorescence 
quantum yield is determined by a comparative method [129]. In this work, AlPcSmix (a 
mixture of differently sulfonated AlPcs) in aqueous media, ΦF 
 
= 0.44 [130] was employed as 
a standard for Pcs, using Equation 1.1 [129].  
                          (1.1) 
where F and Fstd are the areas under the fluorescence curves for sample and the standard, 
respectively, while n and nstd are the refractive indices of solvents in which the sample and 
the reference were dissolved, respectively. A and Astd are the absorbances of the sample and 
reference at the excitation wavelength respectively. Rhodamine 6G standard, dissolved in 
ethanol, ΦF = 0.95 [13], was employed for the determination of ΦF 
𝛷𝛷𝐹𝐹(𝑄𝑄𝑄𝑄)𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐 =  𝛷𝛷𝐹𝐹(𝑄𝑄𝑄𝑄) 𝐹𝐹𝑄𝑄𝑄𝑄𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝐹𝐹𝑄𝑄𝑄𝑄            (1.2) 
value for the QDs. The 
fluorescence quantum yield values of the GSH-CdSe@ZnS after conjugation to the Pc 
(Φ𝐹𝐹𝑄𝑄𝑄𝑄
𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐 ) were obtained using Equation 1.2 
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where ΦF 
 
is the fluorescence quantum yield of the QDs alone and used as standard, 
𝐹𝐹𝑄𝑄𝑄𝑄
𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐 is the fluorescence intensity of the QDs in the conjugate with the Pc when the 
excitation wavelength is that of the QDs (480 nm), 𝐹𝐹𝑄𝑄𝑄𝑄𝑄𝑄 is the fluorescence intensity of the 
QD alone at the same excitation wavelength, both the QDs and conjugates were in the same 
solvent. 
1.5.2 Triplet quantum yields and lifetimes 
The ability of a molecule to populate the triplet excited state and be long lived is essential in 
photodynamic therapy applications. The comparative method was employed for the 
determination of triplet quantum yields using AlPcSmix as standard. Laser flash photolysis is a 
technique used to measure triplet absorbance and this is directly related to the triplet quantum 
yields of photosensitizers [130,131]. The triplet state parameters determined include the 
triplet quantum yields (ΦT) and triplet lifetimes (τT). The triplet lifetimes are determined 
from the triplet decay curve (Fig 1.13) using the OriginPro 8 software. The triplet quantum 
yield (ΦT
 
) is used to determine the population of the phthalocyanine in the triplet state. The 
phthalocyanines usually have triplet absorption spectra in the region of ~ 500 nm.  
 
 
 
 
35 
 
 
Figure 1.13: Typical triplet decay curve of a water soluble Pc (unpublished work). 
 
 
The triplet quantum yields ( SampleTΦ ) may be determined using a comparative method which is 
based on the decay of the triplet state using Equation 1.3 
 
 
SampleStd
StdSample
Std
T
Sample
T ε
ε
∆Α
∆Α
Φ=Φ (1.3) 
 
where ∆Asample and ∆Astd are the changes in the triplet state absorbance of the Pc derivative 
and the standard, respectively. 𝜀𝜀𝑆𝑆𝑐𝑐𝑆𝑆𝑆𝑆𝑆𝑆𝑐𝑐  and 𝜀𝜀𝑄𝑄𝑐𝑐𝑠𝑠  are the triplet state extinction coefficients for 
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the sample and standard, respectively. StdTΦ  is the triplet state quantum yield for the standard, 
where tdT
SΦ = 0.44 for AlPcSmix in water [130]. 
The photophysical parameters i.e. triplet quantum yield (ΦT) and the fluorescence quantum 
yields (ΦF), complement each other and should add up to 1, if there is no energy lost through 
internal conversion. This means that if the triplet quantum yield (ΦT) value is high, a 
corresponding low fluorescence quantum yield (ΦF
 
) will be obtained and vice versa. 
1.5.3 Singlet oxygen quantum yield (Φ∆
The excited triplet state molecule (
) 
3MPc*)  may transfer its energy to ground state triplet 
molecular oxygen (3O2), since the energy of the triplet state molecule (
3MPc*), (Scheme 1.2) 
is higher (~110 – 126 kJ mol-1) than the energy required (~94 kJ mol-1) for the excitation of 
ground state molecular oxygen [132], to form excited singlet oxygen (1O2
 
), through the Type 
II mechanism. 
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Scheme 1.2: Type II mechanism for the photoreaction of MPc leading to the production of 
singlet oxygen. 
 
There are other mechanisms (Type I or Type III) through which the photosensitization 
process could occur. Type I mechanism involves free radicals [132]. While in Type III, 
electron transfer from the substrate to the excited state sensitizer may occur [133]. The 
involvement of Type II mechanism is widespread in oxygen-rich and air saturated 
environments where the oxygen concentration is very high and it is believed that Type II 
mechanism is dominant in photosensitization reactions. The singlet oxygen quantum yields 
(Φ∆
 
) can then be calculated Equation 1.4 
abs
Std
Std
absStd
ΔΔ
I . R
I . R
ΦΦ = (1.4) 
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where StdΔΦ  is the singlet oxygen quantum yield for the standard, R and RStd are the singlet 
oxygen quenchers (e.g tetrasodium α,α-(anthracene-9,10-diyl) dimethylmalonate (ADMA) in 
aqueous media) photobleaching rates in the presence of the respective MPcs under 
investigation and of the standard (such as AlPcSmix) respectively. Iabs 
 
and  I  absstd are the rates 
of light absorption by the MPcs and the standard, respectively. In this method of calculating 
the singlet oxygen, the quencher is normally mixed with the photosensitizer solution and the 
mixture is irradiated typically where the MPc absorbs. The decrease of the quencher 
absorption maximum is monitored spectroscopically and serves as a monitor for singlet 
oxygen generation. 
1.5.4 FRET Parameters 
FRET efficiency (Eff) can be determined from the fluorescence quantum yields of the donor 
in the absence (ΦF (QDs)) and presence (ΦF (QDs)conjugate) of the acceptor using Eq. 1. 5 [134]: 
 
𝐸𝐸𝑓𝑓𝑓𝑓 = 1 − 𝛷𝛷𝐹𝐹(𝑄𝑄𝑄𝑄 )𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐
𝛷𝛷𝐹𝐹(𝑄𝑄𝑄𝑄 )  
 
 
 
FRET efficiency (Eff) is related to r (Å) by Eq. 1.6 [134] 
 
𝐸𝐸𝑓𝑓𝑓𝑓 = 𝑅𝑅06
𝑅𝑅06+𝑟𝑟6          (1.6) 
 
(1.5) 
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where r represents the centre-to-centre separation distance (in Å) between the donor and the 
acceptor, R0 
 
(the Förster  distance, Å) is the critical distance between the donor and the 
acceptor molecules at which the efficiency of energy transfer is 50 % and depends on the 
quantum yield of the donor Eq. 1.7 [134]: 
R06 = 8.8 x1023 𝑘𝑘2𝑐𝑐−4Φ𝐹𝐹(𝑄𝑄𝑄𝑄𝑄𝑄)𝐽𝐽        (1.7) 
 
where k is the dipole orientation factor, n is the refractive index of the medium,  ΦF (QDs )is 
the fluorescence quantum yield of the donor and J is Förster overlap integral, given by Eq. 
1.8 
 
𝐽𝐽 = ∫ 𝑓𝑓(𝑄𝑄𝑄𝑄𝑄𝑄) (λ)εMPc (λ)λ4 ∂λ           (1.8) 
 
Where 𝑓𝑓(𝑄𝑄𝑄𝑄𝑄𝑄) is the normalized QD emission spectrum. εMPc  and λ are respectively, the molar 
extinction coefficient and the wavelength at the Q band maxima for Pc. It is assumed that k2
 
 
is 2/3.This assumption is normally made for donor-acceptor pairs in a liquid medium, which 
are considered to be isotropically oriented during their lifetime. FRET parameters were 
computed using the program PhotochemCAD [134]. 
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1.6 Summary of aims 
1. Determine possible cytotoxic effects of a set of quantum dots (different cores, coreshells 
and capping agents) by systematic photophysical evaluation in vivo and in vitro. 
2. Use the quantum dots determined to be the least cytotoxic (GSH-CdSe@ZnS) to 
conjugate to the ClGaPc(COOH)8 to form a bi-functional anti-cancer agent by 
incorporating the properties of the quantum dots and phthalocyanine. Also evaluating the 
photophysical parameters of the core (GSH-CdSe) QDs and different sized coreshell 
(GSH-CdSe@ZnS) QDs when conjugated to the ClGaPc(COOH)8
3. Conjugate the ClInPc(COOH)
. 
8 separately to magnetic nanoparticles to form a bi-
functional anti-cancer with the intention of combing hyperthermia and PDT. In addition, 
GSH-CdSe@ZnS QDs were also conjugated separately to ClInPc(COOH)8
4. Develop a multifunctional nanocomposite composed of GSH-CdSe@ZnS, magnetic 
nanoparticles and ClInPc(COOH)
 to form a bi-
functional anti-cancer agent (PDT and imaging). Evaluate the photophysical parameters 
of the conjugates. 
8, 
5. Application and testing some of the conjugates in PDT studies using human carcinoma 
BON cells and in vivo using chicken chorioallantoic membrane assay (CAM). 
which has potential to detect, monitor and treat 
cancer. The photophysical parameters of the nanocomposite were evaluated. 
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This chapter provides information on the materials, instrumentation and synthetic 
procedures used in this work. 
CHAPTER 2 
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2. Experimental 
2.1 Materials 
For synthesis and characterization: Benzene-1,2,4,5-tetracarboxylic dianhydride 
(pyromellitic dianhydride), 1,8-diazabicyclo [5.4.0]undec-7-ene (DBU), indium chloride, 1-
ethyl-3-(3-dimethyl aminopropyl) carbodiimide hydrochloride (EDC),  N-
hydroxysuccinimide (NHS), CdO, sulphur powder, zinc powder, glutathione (GSH), oleic 
acid, tetraethoxysilane (TEOS), 1-octadecene, trioctylphosphine oxide (TOPO) and sellinium 
powder. Aluminium oxide 90 (0.04 – 0.200 mm) and sodium and potassium hydroxide pellets 
(98%)  were purchased from Sigma–Aldrich. AlPcSMix (containing a mixture of sulfonated 
derivatives), used as a standard was synthesized according to literature methods [135]. 
 
Solvents: Methanol, chloroform, acetone, ethanol, dimethylsulfoxide (DMSO), toluene, 
hydrochloric acid (32%) were purchased from Fluka, while dimethyl formamide (DMF) was 
purchased from SAARCHEM. 
All solvents were dried as described by Perrin and Armarego [136] before use. All the other 
reagents used were of analytical grade and used without prior purification.  
 
Aqueous solutions were prepared using Millipore water Milli-Q Water Systems (Millipore 
Corp., Bedford, MA, USA). Phosphate-buffered solutions (PBS) of pH 7.4 were prepared 
using appropriate amounts of Na2HPO4, KH2PO4 
 
and the respective chloride salts, and 
dissolved in ultra-pure water. 
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Cell work 
Human pancreatic carcinoid BON cells, Ham’s F-12/Dulbecco's Modified Eagle's medium 
(DMEM) (1:1) medium supplemented with 10% fetal calf serum (FCS, Biochrom), L
 
-
glutamine, penicillin and 100 µg/ml streptomycin, 1% glutaraldehyde, 0.1% crystal violet, 
2% Triton X-100, 1 % Trypsin/Ethylenediaminetetraacetic acid (EDTA) were purchased 
from Biochrom AG, Berlin, Germany. 
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2.2 Instrumentation and Equipment 
i. Ultra violet –visible spectra (UV-Vis) were recorded on a Shimadzu UV 2550 
spectrophotometer. All spectral measurements were performed in a quartz cell of 1 cm 
path length. 
 
ii. Infrared spectra (KBr pellets) were recorded on a Perkin–Elmer Spectrum 100 ATR FT-
IR and Perkin–Elmer Spectrum 400FT-IR spectrometers. 
iii. Elemental analyses were carried out on a Vario EL III MicroCube CHNS Analyzer. 
iv. Fluorescence excitation and emission spectra were recorded on a Varian Eclipse 
spectroflourimeter. 
 
v. Mass spectral data were collected with a Bruker AutoFLEX III Smartbeam TOF/TOF 
Mass spectrometer. The instrument was operated in positive ion mode using a mass range 
of 400-3000 amu. The voltage of the ion sources were set at 19 and 16.7 kV for ion 
sources 1 and 2, respectively, while the lens was set at 8.50 kV. The reflector 1 and 2 
voltages were set at 21 and 9.7 kV, respectively. The spectra were acquired using 
dithranol as the MALDI matrix, using a 354 nm nitrogen laser as the ionising source. 
 
vi. X-ray powder diffraction (XRD) patterns were recorded on a Bruker D8, Discover 
equipped with a proportional counter, Using Cu-K radiation ( = 1.5405 Å, nickel filter). 
Data were collected in the range 2θ = 15o to 60o, scanning at 1 min-1. The filter time-
constant and the slit width were 2.5 s per step and 6.0 mm respectively. Samples were 
placed on a silicon wafer slide. The X-ray diffraction data were processed using Eva 
(evaluation curve fitting) software. Baseline correction was performed on each diffraction 
45 
 
pattern by subtracting a spline fitted to the curved background and the full width at half 
maximum values used in this work were obtained from the fitted curves. 
 
vii. Transmission electron microscopy (TEM) images were obtained using ZESISS LIBRA® 
120 transmission electron microscope which operates at 90 kV, Formvar / carbon coated 
300 copper mesh grids. 
 
viii. 1H-Nuclear magnetic resonance spectra (1
 
H-NMR) were recorded using a deuterated 
solvent using a  Bruker AMX 400 MHz NMR spectrometer. 
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Figure 2.1: Schematic diagram of time-correlated single photon (TCSPC) set up. (MCP)-
PMT= Monochromator photomultiplier tube, PC=Personal computer. 
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ix. Fluorescence lifetimes were measured using a time correlated single photon counting 
(TCSPC) setup (Figure 2.1) (FluoTime 200, Picoquant GmbH) with a diode laser (LDH-
P-670 and LDH-P-480 (for QDs)  with PDL 800-B, Picoquant GmbH, 670 nm or 480 nm, 
20 MHz repetition rate, 44 ps pulse width). Fluorescence was detected under the magic 
angle with a Peltier cooled photomultiplier tube (PMT) (PMA-C 192-N-M, Picoquant) 
and integrated electronics (PicoHarp 300E, Picoquant GmbH). A monochromator with a 
spectral width of about 8 nm was used to select the required emission wavelength band. 
The response function of the system, which was measured with a scattering Ludox 
solution (DuPont), had a full width at half-maximum (FWHM) of 300 ps. All 
luminescence decay curves were measured at the maximum of the emission peak and 
lifetimes were obtained by deconvolution of the decay curves using the FluoFit Software 
program (PicoQuant GmbH, Germany). The support plane approach [13] was used to 
estimate the errors of the decay times. 
 
x. A laser flash photolysis (Figure 2.2) system was used to determine the triplet quantum 
yields and lifetimes. The excitation pulses were produced by a Quanta-Ray Nd:YAG laser 
(1.5 J/9 ns), pumping a Lambda Physik FL 3002 dye laser (Pyridin 1 in methanol). The 
analysing beam source was from a Thermo Oriel xenon arc lamp and a photomultiplier 
tube was used used as a detector. The signals were recorded with a two channel 300 MHz 
digital oscilloscope (Tektronix TDS 3032C). 
xi. Column chromatography was performed on aluminium oxide 90 (0.04 – 0.200 mm). 
xii. Thermal gravimetric analysis (TGA) were performed on a Shimadzu DTG-TG 60H 
with a gas flow of 120 ml/min and operated under nitrogen atmosphere. 
xiii.  Fluorescence microscope from Zeiss (Axioskop 40, Jena, Germany), 546 nm, was 
employed. 
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Nd: YAG laser Dye laser Focussing mirror
Xenon lamp Collimating lens
Sample cell holder
Monochromator with PMT
Oscilloscope
 
Figure 2.2 Schematic representation of laser flash photolysis set-up.  PMT= photomultiplier 
tube. 
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2.3 Synthesis 
The synthesis of the following QDs have been reported before: L-cysteine-CdTe [137], TGA-
CdTe [137], MPA-CdTe [137, 138], MPA-CdTe@ZnS [139], GSH-CdTe@ZnS [84] and 
TGA-CdSe [138,140].  
2.3.1 Synthesis of CdSe@ZnS-GSH QDs 
GSH-capped CdSe@ZnS QDs were synthesized via previously described methods [141]with 
slight modifications. Briefly, 1.3 g (10.1 mmol) of CdO was added to a mixture of 30 mL 
oleic acid and 50 mL of 1-octadecene in a three-necked flask. The solution was heated to 
~260 ºC under reflux and maintained under N2 atmosphere to obtain a clear solution. The 
temperature of the solution was then lowered to 230 ºC and a solution of Se powder (0.3 g, 
3.8 mmol) and 0.1 M TOPO in 25 mL of 1-octadecene (which was stirred for 24 hrs to obtain 
homogeneous slurry under N2
 
 atmosphere) was added to the flask. The size of the core CdSe 
QDs was controlled by further lowering the temperature of the solution.  
Once the desired size of the core CdSe QDs was obtained, Zinc powder (0.40 g, 6.2 mmol), 
dissolved in 20 mL oleic acid and 30 mL 1-octadecene was added. Sulphur powder, 0.16 g 
(5.0 mmol) was also dissolved in 20 mL oleic acid and 30 mL 1-octadecene were alternately 
injected into the TOPO capped CdSe QDs solution to obtain the TOPO-capped CdSe@ZnS 
QDs. The QDs were then purified by washing with methanol followed by acetone. The 
TOPO capped CdSe@ZnS QDs are hydrophobic and therefore not suitable for biological 
applications. Water soluble GSH-capped CdSe@ZnS QDs were obtained via the ligand 
exchange route. Firstly, GSH-KOH methanolic stock solution was prepared by adding 2 mL 
(2 g (6.5 mmol)) of GSH separately to 3.0 g (53.4 mmol) of KOH in 40 mL methanol. The 
purified TOPO-capped CdSe@ZnS QDs were then re-dispersed in chloroform and GSH-
KOH methanolic solution was subsequently added followed by the addition of Millipore 
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water. The solution was allowed to stir for 1 hr. The obtained water-soluble QDs were 
precipitated out with methanol, washed and centrifuged several times with acetone and dried 
under vacuum. The extinction coefficients of GSH-CdSe@ZnS QDs (used to determine 
concentration) were determined using literature methods [142]. The same method was used to 
estimate the extinction coefficient when GSH-CdSe@ZnS QDs were linked to the 
phthalocyanines employed in this work
The syntheses of the following pthalocyanines; AlPc(COOH)
. 
8 and GaPc(COOH)8 have been 
reported before [143,144]. The synthesis of amino (APTES) functionalized iron oxide 
(Fe3O4
2.3.2 Synthesis of ClInPc(COOH)
) magnetic nanoparticles (MNPs) has been described in literature before [99]. 
Octacarboxypthalocyaninto indium (III) chloride was synthesised according to the methods 
reported for other octacarboxy phthalocyanines [143,144] as follows: a mixture of benzene-
1,2,4,5- tetracarboxylic dianhydride (pyromellitic dianhydride 2.50 g, 11.5 mmol), urea (13.0 
g , 0.22 mol),  InCl
8 
3 (23.5 mmol, 5.19 g) and DBU (0.1 g , 0.7 mmol) as catalyst was heated 
to 250 °C in a flask until the reaction mixture was fused. The product was washed with water, 
acetone and 6 M hydrochloric acid. After drying, the product was hydrolyzed in 20% H2SO4 
Yield: (47%) IR (KBr, cm
for 72 hrs. The products were further purified using column chromatography as explained in 
literature [143, 144]. 
-1): 3432 (OH) 1716 (C=O) 1381, 1273, 1184 (C-O). 1H NMR 
(400 MHz, D2O): 7.82 ppm (s, 8H, Pc-H), 11.56 ppm (s, 8H carboxylic H). UV-Vis (0.1 M 
NaOH): λ max, nm (log ε), 691 (5.1), 351 (5.5) MS (m/z) : Calculated 1014 g/mol Found: 
1010 (M-4H). Calculated for C40H16O16N8InCl: C 47.34, H 1.58, N 11.04; Found C 47.57, H 
1.70, N 12.47 
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2.3.3. Covalent linking of GSH-CdSe or GSH-CdSe@ZnS to 
octacarboxyphthalocyanine (Pc) [(ClInPc(COOH)8, ClGaPc(COOH)8 or 
ClAlPc(COOH)8
Pcs [(ClInPc(COOH)
)]. 
8,  ClGaPc(COOH)8 or  ClAlPc(COOH)8
2.3.4. Covalent linking of ClInPc(COOH)
)] were covalently linked to 
GSH-CdSe or GSH-CdSe@ZnS as follows: Pc (0.7 mmol ) was dissolved in  10 ml dilute 
NaOH, then 2 mL of 1.2 mM EDC was added to activate the carboxylic group (-COOH) of 
the Pc. The mixture was allowed to stir for 48 hrs at room temperature under argon 
atmosphere. After this time, a mixture containing 2 mL of 1 mM NHS and GSH-CdSe@ZnS 
(0.003 g) was added to the activated Pc and the mixture was stirred for 12 hrs to allow 
conjugation of the Pc to the QDs to take place.  
8 to Fe3O4
ClInPc(COOH)
 magnetic nanoparticles, (Scheme 
5.1). 
8  (15 mg, 9.9 x 10
-6 mol) was dissolved in 10 ml  of PBS pH 7.4. EDC (0.23 
g, 1.2 mmol) and NHS (0.115 g, 1 mmol) were added and the solution stirred for 3 hrs. The 
Fe3O4 magnetic nanoparticles (5 mg), dissolved in 10 mL of PBS pH 7.4, were added to the 
activated ClInPc(COOH)8. The mixture was stirred for 12 hrs at room temperature under N2 
gas flow. The product was precipitated with ethanol, washed with ethanol and centrifuged to 
remove excess reactants. A magnet was employed to remove unreacted Pcs. The conjugate is 
represented as ClInPc(COOH)8
 
-MNPs. 
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2.3.5 Covalent linking of GSH-CdSe@ZnS QDs to Fe3O4
GSH-CdSe@ZnS QDs (10mg) was dissolved 5 ml of PBS at pH 7.4. EDC (0.23 g, 1.2 mmol) 
and NHS (0.115 g, 1 mmol) were added and the solution stirred for 3 hrs. The Fe
 magnetic nanoparticles 
3O4 
magnetic nanoparticles (5 mg), dissolved in 10 mL of PBS pH 7.4, were added to the 
activated QDs. The mixture was stirred for 12 hrs at room temperature under N2
2.3.6 Coating the QDs-MNPs conjugate with silica 
 gas flow. 
The product was precipitated and washed with ethanol, and centrifuged to remove excess 
reactants. A magnet was employed to remove unreacted QDs. The conjugate is represented as 
QDs-MNPs. 
The QDs-MNPs were encapsulated with silica; the silica layer is known to protect therapeutic 
or diagnostic molecules (i.e QDs-MNPs conjugate in this work) from degradation in the 
physiological environment. The mesoporous silica shell was formed by simultaneous sol-gel 
polymerization of tetraethoxysilane (TEOS). The QDs-MNPs conjugate was coated with 
silica using methods that have been described in literature [145]. Briefly, to a mixture of 1.77 
ml of Triton-X 100, 1.8 mL of n-hexanol and 7.5 mL of cyclohexane 0.48 ml of QDs-MNPs 
solution (5 mg in 5 mL of PBS pH 7.4), 0.1 ml of TEOS, 6 ml of NH4
 
OH were consecutively 
added. The resulting mixture was stirred for 24 hrs. After this time, 20 mL of acetone was 
added followed by centrifuging and washing with ethanol. The resulting conjugate is 
represented as silica coated QDs-MNP. 
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2.3.7 Synthesis of multi-functional GSH-CdSe@ZnS QDs-magnetic nanoparticles –
indium octacarboxyphthalocyanine nanocomposite, (Scheme 5.2) 
ClInPc(COOH)8 was attached on the surface of the silica coated-QDs-MNPs conjugate by 
taking advantage of the –NH2 groups and using them as points of attachment. 
ClInPc(COOH)8 was covalently linked to silica coated QDs-MNPs as described in 2.3.3 and 
is represented as ClInPc(COOH)8
 
-QDs-MNPs.  
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2.4 Cell studies 
Human pancreatic carcinoid BON cells were used in this study. The BON cells were grown 
in a 1:1 mixture of Dulbeco modified eagle medium (DMEM) and Ham’s F-12 medium 
containing 10% FCS and 1 % L-glutamine. The cell lines were kept at 37°C in a humidified 
atmosphere (5 % CO2
 
). The culture media was changed every second day and once a week 
the cells were passaged using 1% Trypsin/EDTA. 
2.4.1 Uptake of GSH-CdSe@ZnS QDs 
Cells grown on glass cover slips were incubated with QDs at concentrations of 0.2 and 0.4 
µM for 4, 8 and 24 hrs. After the incubation period, samples were washed twice with PBS, 
then fixed with methanol (99%) at -20˚C for 20 min and again washed with PBS. 
Photographed area contained at least n = 10 cells.  Uptake was measured using fluorescence 
microscope. 
 
2.4.2 Cytotoxicity 
The changes in cell numbers induced by QDs were evaluated by crystal violet staining as 
described in literature [146]. The growth inhibitory effect of the QDs on BON cancerous cells 
were performed after 48 hrs of continuous incubation with different concentrations of the 
respective QDs ranging from 0.1 to 5 µM. The cells in 96-well plates were fixed with 1% 
glutaraldehyde. The cells were then stained with 0.1 % crystal violet in phosphate buffered 
saline (PBS), the unbound QDs were removed by washing with water.  
55 
 
Bound QDs crystal violet was solubilized with 0.2 % Triton-X-100 in PBS. Light extinction, 
which increases linearly with the cell number was analysed at 570 nm using an ELISA 
microplate -reader. 
 
2.4.3 Chicken chorioallantoic membrane assay (in vivo) 
Embryotoxicity in terms of lethality and vein network degeneration was evaluated by chicken 
chorioallantoic membrane assay (CAM). Fertilized chicken eggs were incubated in an 
incubator at 37 ˚C in constant humidity for 15 days. After 7 days of incubation, a window 
was cut into the shell of each egg, then sealed with a tape and bred in the incubator for the 
following 4 days. On day 11 a tape was removed and the CAMs were treated with QDs – 
topically or intravenously. In the case of topical application a small silicone ring (5 mm in 
diameter) was placed onto the CAM and QDs in PBS or PBS alone were added (100 µl per 
egg, each day until day 15); in case of intravenous application a superficial CAM vein was 
injected with 10-15 µl of QDs-NaCl or NaCl using 301/2 
 
G needle. Concentration of injected 
compound was counted based on total blood volume of 11 day-old embryo [147]. 
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2.5 Photophysical studies 
2.5.1 Fluorescence quantum yields and lifetimes 
The fluorescence quantum yield for the Pcs were determined by a comparative method [129]. 
AlPcSmix as standard in aqueous media, ΦF = 0.44 [130] was employed for the Pcs, 
Equation 1.1.  For the determination of ΦF values of QDs and their conjugates, Rhodamine 
6G standard dissolved in ethanol, ΦF = 0.95 [13] was employed.  The absorbances of the 
solutions at the excitation wavelength were about 0.05 to avoid inner filter effects. The 
fluorescence lifetimes were evaluated from the tri-exponential decay curve of GSH-CdSe and 
GSH-CdSe@ZnS.  A good fitting was judged by weighted residuals and χ2 
 
values. The 
calculation of the average fluorescence lifetime for the conjugates and QDs was achieved 
using the value obtained from the fit. 
2.5.2 Triplet quantum yields and lifetimes 
The decay kinetics of the triplet absorption of the Pcs were recorded using laser flash 
photolysis setup, Figure 2.2. The absorbance of the sample solutions and that of the standard 
were adjusted to be nearly 1.5 at their Q band maximum. All samples were introduced into a 
1 cm quartz cell and then bubbled with argon for 10 min to remove dissolved oxygen before 
taking any readings. The triplet quantum yields of the sample phthalocyanines alone and in 
the presence of QDs were determined using Equation 1.3. Using AlPcSmix  as standard in 
water tdT
SΦ = 0.44 [130].Triplet lifetimes were determined from kinetic data obtained using 
ORIGIN Pro software to fit the kinetics decay curves. 
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CHAPTER 3 
This chapter presents the results of the characterization and toxicity of quantum dots. 
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3.1.1 XRD 
X-ray diffraction patterns of L
 𝑄𝑄 =  0.9 𝜆𝜆
𝐵𝐵𝑐𝑐𝑐𝑐𝑄𝑄𝐵𝐵
                       (3.1) 
-cysteine-CdSe and GSH-CdSe@ZnS QDs are shown in 
Figure 3.2 as examples. Using XRD data, the sizes of QDs were determined using the 
Debye-Scherrer equation (Equation 3.1) [148].  
 
Where D is the mean diameter of the QDs in nm, 𝜆𝜆  the wavelength of the X- ray source, 𝐵𝐵 
the angular position of the peak.A typical zinc blende crystal structure with planes at [111], 
[220], and [311] was obtained for CdSe QDs with peaks at 26.8, 44.0 and 52.1. The peaks for 
CdSe@ZnS QDs were at 28.6, 47.6 and 56.2. Following the growth of ZnS shells on the core 
CdSe, the peak position shifted to higher angles and thus, confirmed the formation of 
CdSe@ZnS core shell QDs. The broadening and shift of the diffraction patterns to higher 
angles due to the growth upon adding the shell has been reported before and is typical of the 
formation of the shell over the core [76, 84]. All the QDs showed similar behaviour to that 
shown in Figure 3.2.Using Eq. (3.1) the sizes of QDs were calculated and the values are 
summarized in Table 3.1. The size of the QDs obtained ranged between 2.0 and 3.5 nm. 
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Figure 3.2: XRD spectra of the L-cysteine-CdSe and GSH-CdSe@ZnS QDs. 
 
3.1.2. UV/vis absorption and emission spectroscopy 
The absorption and emission spectra of the QDs (GSH-CdSe@ZnS used as an example) in 
water are shown in Figure 3.3. The emission maxima are shown in Table 3.1. All QDs 
exhibited broad absorption and well-resolved emission spectra. The emission maxima ranged 
from 539 to 633 nm, depending on the size and structure of the QDs as is typical of quantum 
dots [75-80]. Using  Rhodamine 6G in ethanol as  reference (ΦF = 0.95) [13],  fluorescence 
quantum yields of the synthesized QDs were calculated using Eq. (1.1) and the values were 
found to be 0.61, 0.41, 0.72, 0.47, 0.016, 0.14 and 0.44 for GSH-CdSe@ZnS, GSH-
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CdTe@ZnS, MPA-CdTe@ZnS, MPA-CdTe, TGA-CdSe, TGA-CdTe and L-cysteine-CdTe, 
respectively (Table 3.1). 
 
 
 
 
 
Figure 3.3: UV/vis absorption (dotted line) and fluorescence emission (spectra solid line) of 
GSH-CdSe@ZnS. Excitation wavelength = 300 nm. 
 
3.1.3 Transmission electron microscopy (TEM) images 
TEM was employed to study the morphology of the QDS. Figure 3.4 (A and B) shows the 
TEM images of the coreshell and core, respectively (MPA-CdTe@ZnS and MPA-CdTe used 
as examples). The coreshell showed some level of aggregation compared to the core alone, 
thus suggesting that the coreshell influences the surface morphology and size.  
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Table 3.1: Size, emission maxima and fluorescence quantum yields of different QDs in 
water. 
QDs Size, nm λnm ΦF 
GSH-CdSe@ZnS 2.8 580 0.61 
GSH-CdTe@ZnS 3.1 600 0.41 
MPA-CdTe@ZnS 3.1 557 0.72 
MPA-CdTe 2.7 563 0.47 
TGA-CdSe 2.0 539 0.016 
TGA-CdTe 3.2 609 0.14 
L-cysteine-CdTe 3.5 633 0.44 
 
 
 
Figure 3.4: TEM images for (A) MPA-CdTe@ZnS and (B) MPA-CdTe. 
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3.2 Toxicity studies 
3.2.1 Growth inhibitory effect of QDs  
TGA-CdSe, Figure 3.5 (b), GSH-CdTe@ZnS Figure 3.5 (c) and GSH-CdSe@ZnS Figure 
3.5 (a) inhibited the growth of BON cells dose-dependently. MPA-CdTe@ZnS, Figure 3.5 
(d) exhibited pronounced growth inhibitory effect, resulting in decreased cell numbers of 
almost 100% even at low nanomolar concentrations (20 nM). MPA-CdTe, Figure 3.5 (d) 
which was investigated as the core counterpart of MPA-CdTe@ZnS, was less toxic than the 
ZnS-bearing QD, but still inhibited the growth of BON cells at nanomolar concentrations. 
The IC50 (half maximal inhibitory concentration) 
 
value of MPA-CdTe was calculated to be 
0.054 µM (Figure 3.5). TGA-CdTe and L-cysteine-CdTe QDs were not tested in vitro 
because they precipitated from the medium, which was an unexpected finding as both QDs 
were water soluble.  
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QD IC50 
GSH – CdTe@ ZnS 0.7 µM 
GSH – CdSe@ZnS 0.38 µM 
TGA – CdSe 2.9 µM 
MPA - CdTe 0.054 µM 
MPA – CdTe@ZnS n.d. very high dark toxicity 
n.d = not determined 
Figure 3.5: Determination of IC50 values using BON cells. Data are given as percentage of 
untreated controls, which were set 100% (mean ± S.D. of 3 independent experiments).IC50
 
 
value determined after 48 h of incubation with the respective QD.  
3.2.2 Cytotoxicity of QDs  
The cytotoxicity of QDs displaying no embryotoxicity was determined by measuring the 
release of lactase dehydrogenase (LDH) into the supernatant of BON cells. BON cells were 
exposed to GSH-CdSe@ZnS QDs (as an example) in concentrations ranging from 0.1 to 5 
mM for 6 or 24 hrs. In BON cells treated with 0.1 and 0.2 mM of the QDs, only slight 
increases in LDH release (<10%) were observed, regardless of the length of incubation, 
Figure 3.6. GSH-CdSe@ZnS at 0.5 mM caused an increase in LDH release of >10% after 6 
hrs and >20% after 24 hrs. At 5 mM, the release of LDH into the supernatant increased by 
more than 30% compared to untreated cells after 6 and 24 hrs.  
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The results indicated that GSH-CdSe@ZnS did not directly affect cell membrane integrity 
and did not have immediate cytotoxic effects in BON cells at concentrations below 0.5 mM 
(Figure 3.6). It will also be shown with chick chorioallantoic membrane (CAM) assays that 
the GSH-CdSe@ZnS was the least toxic in vitro. 
 
 
 
 
 
 
 
 
 
Figure 3.6: Determination of QD-induced cytotoxicity. LDH release into the supernatant of 
BON cells was determined after 6 and 24 hours of continuous incubation with increasing 
concentrations of GSH-CdSe@ZnS. Data are given as percentage of untreated controls, 
which were set 100 % (mean ± standard error of mean (SEM) of 3 independent experiments). 
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3.2.3 Cellular uptake of QDs  
Incubating BON cells with GSH-CdSe@ZnS QDs (0.2 and 0.4 mM) for 4–24 hrs led to a 
time and dose-dependent intracellular accumulation of QDs (Figure 3.7). When 
administering 0.2 mM of GSH-CdSe@ZnS QDs, a time-dependent increase in intracellular 
accumulation was observed during the first 4 hrs. Higher concentrations (i.e 0.4 mM) 
increased the intracellular accumulation within the first 4 hrs, reflecting the dose-dependency 
of the QD-uptake. Increasing the incubation time to 8 and 24 hrs led to an additional increase 
in QD-uptake only at the concentration of 0.2 mM, whereas at 0.4 mM a slight loss of 
intracellular QD fluorescence was observed, (Figure 3.7). Moreover, the distribution patterns 
changed from an even and diffuse (0.2 mM) to an uneven and more punctuate intracellular 
fluorescence signal at 0.4 mM. We suggest the drop of fluorescence intensity in combination 
with the changed intracellular distribution pattern may occur due to an accumulation of the 
QDs in subcellular compartments (e.g organelles, vacuoles). However, further experiments 
will have to determine the exact intracellular localization and distribution, since this may be 
of great importance for the suitability and mode of action of QD-based biomedical 
applications. 
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4 h                               8 h                                     24 h 
 
  
 
 
 
Figure 3.7: Time- and dose-dependent uptake of GSH-CdSe@ZnS QD in BON cells. QD 
uptake was determined by fluorescence microscopy after 4–24 hours of incubation with 0.2 
0.2 
µM 
0.4 
µM 
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mM or 0.4 mM GSH-CdSe@ZnS. Representative findings of three independent experiments 
with n = 10–50 cells per concentration and incubation time. Upper panel: phase-contrast 
images; lower panel: corresponding fluorescence micrographs.  
 
3.2.4 Embryotoxicity  
Evaluation of the toxicity of QDs in vivo was determined by performing chick chorioallantoic 
membrane (CAM) assays. QDs were either injected into the CAM-vein or applied topically to 
11-days old fertilized chicken eggs. Initially, the TGA-capped CdSe QDs were investigated. 
Topical application of the IC50 (i.e 2.9 µM) led to death in 40% and 60 % was obtained when 
applied intravenously, (Table 3.2). Next, we evaluated GSH-capped QDs; GSH-CdTe@ZnS 
QDs applied topically at 1 µM showed no influence on embryo vitality, while administered 
intravenously at 0.6 µM embryo death in almost 90% was observed. Finally, GSH-
CdSe@ZnS QDs neither affected the vascular network and microvessel structure of the 
developing CAM, nor influence chicken embryo vitality at the IC50
 
 of 0.4 µM. These 
observations were regardless of the mode of application (i.e intravenously or topically). All 
chicken embryos were sacrificed at the end of the study and examined for developmental 
defects such as encephalic hernia or cleft beak [149]. However, no such defects were found in 
GSH-CdSe@ZnS QDs injected embryos (data not shown), further supporting the finding that 
GSH-CdSe@ZnS QDs do not cause embryotoxicity. 
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Table 3.2: QDs were applied topically (A) or injected (B) into the CAM-vein of 11-days old 
fertilized chicken eggs. 
(A) 
QDs Concentration Topical application, % of 
survival 
TGA-CdSe 2.9 µM 60 
GSH-CdTe@ZnS 1 µM 1 
GSH-CdSe@ZnS 0.4 µM 100 
 
(B) 
QDs Concentration Injected, % of survival 
TGA-CdSe 1 µM 40 
GSH-CdTe@ZnS 0.6 µM 11 
GSH-CdSe@ZnS 0.4 µM 100 
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3.2.5 Discussion 
Many studies suggest ion leakage from the core of QDs, especially Cd2+
Capping of QDs plays an important role in preventing degradation and subsequent release of 
cytotoxic heavy metal ions. Thus, we examined QDs with the same core and shell but with 
different cappings. CdTe@ZnS QDs with GSH capping (IC
 [150], which has 
become a significant problem because the cores of QDs are mostly synthesized from heavy 
metals. However, stable coating with a shell and capping may effectively prevent ion leakage 
and additionally protect the core from air oxidation [151]. In our study, we could demonstrate 
that GSH-CdSe@ZnS QDs were stable structurally and potentially safe for biomedical use as 
shown in respective in vitro and in vivo investigations.  
50 = 
Our data are somewhat in discordance to findings reported by Lee et al. who observed that 
MPA-capped CdSe@ZnS QDs did not cause toxicity in living organisms even at 
concentration 2500 mg/l after 48 hrs of exposure to the systems [152]. As the study of Lee 
and co-workers employed the so called "daphnia test” to estimate QD toxicity in vivo, it is not 
surprising that the IC
0.7 µM) showed decidedly 
lower cytotoxicity than those with MPA capping (very high). MPA-CdTe@ZnS QDs killed 
almost 100% of incubated cells even at low nanomolar concentrations (20 nM), while GSH-
capped QDs (GSH-CdTe@ZnS) exhibited comparatively low cytotoxicity in BON cells, even 
at higher doses.  
50 values determined with this method differ from those of the in vitro 
tests on human cells used in our investigation. 
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 Compared to the direct measurement of growth inhibition and cytotoxicity in our study, the 
daphnia test does not directly measure cytotoxicity or death but uses the treatment-induced 
loss of mobility of a water-living small crustacean (Daphnia magna)  as a read-out for the 
toxicity of a compound. However, the exact reasons for the discrepancy between our findings 
and those of Lee et al. remain to be elucidated. Nevertheless, in the context of our 
investigation MPA-capped CdSe-QDs were found to be too toxic to be favourable for 
biomedical applications and were thus excluded from further in vivo examinations. Changes 
in the core materials of QDs can have an impact on their toxicity. It has been previously been 
shown that not all of the QD cores were completely coated with a ZnS shell (using the one-
pot synthesis also employed in this work) due to the lattice mismatch between core and shell 
[153]. This mismatch is estimated to be ~16%, which makes these QDs susceptible to 
degradation. For CdSe and ZnS, the lattice mismatch is ~12% [154], which means less 
degradation of the QDs will occur. As a result, CdSe@ZnS QDs should be less toxic and 
more stable than CdTe@ZnS QDs, as observed in this work for GSH- CdTe@ZnS and 
CdSe@ZnS QDs.  
Additionally; we investigated QDs without shell but with TGA capping. As mentioned above, 
well-matched capping and proper structure of the core are very important. We found that 
TGA-CdSe exhibited lower cytotoxic potency than GSH-CdSe@ZnS. This is an unexpected 
finding, since QDs with a shell are supposed to be less toxic than those without shell [151]. It 
can be speculated that TGA somehow stabilized the structure of the core and prevented 
oxidation and/or ion leakage. However, such a hypothesis requires further examination and 
will be addressed in further studies. GSH-CdTe@ZnS and TGA-CdSe QDs showed marked 
toxicity in vivo which rejected them from further investigations.  
Two other QD types (i.e L-cysteine-CdTe and TGA-CdTe) were not soluble in the 
experimental medium, and thus, excluded from further studies. When QDs become unstable, 
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they precipitate out of solution. This can be caused by the capping materials or by 
interactions with medium components (e.g serum, salts and proteins). It has been reported 
that instability of surface ligands can allow QD cores to degrade or induce air oxidation, 
which in turn releases cadmium ions to the environment [155].  
Biocompatibilities as well as solubility are essential requirements for biological uses of QDs. 
A number of studies have been published that described QDs to be biocompatible and 
without impact on embryonic development or vitality [156]. Our in vivo study, also found no 
evidence teratogenic effects after injection with QDs. Particularly, GSH-CdSe@ZnS QDs 
induced no embryotoxicity, which suggests that this QD in can be safely used in biomedical 
research in the reported doses (i.e 0.1– 0.4 mM). Moreover, QDs have become widely used 
probes for in vitro and in vivo imaging as well as diagnostic agents for tumor monitoring or 
photodynamic therapy [157]. Here, we have shown that non-toxic concentrations of GSH-
CdSe@ZnS QDs of 0.2 mM and 0.4 mM achieve sufficient cellular uptake to obtain distinct 
fluorescent signals (Figure 3.7). This suggests that in addition to their properties as a carrier 
of photosensitizers for PDT, GSH-CdSe@ZnS QDs may also be interesting for tumor 
monitoring and diagnosis. 
We conclude that suitable capping and encapsulation can remarkably reduce the toxicity of 
QDs. CdSe QDs with ZnS shell and GSH capping appear to be promising candidates for 
biological uses and merit further investigations. 
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CHAPTER 4 
This chapter presents the characterization of the phthalocyanine-quantum dot 
conjugates. 
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4. Conjugation of Pcs with QDs 
4.1 Characterization  
4.1.1 ClInPc(COOH)8 
Gallium and aluminum octacarboxy phthalocyanines (ClGaPc(COOH)
alone 
8  and 
ClAlPc(COOH)8) are known complexes and gave satisfactory UV-Vis , FT-IR, NMR 
elemental analysis and mass spectroscopy results. However, the synthesis of ClInPc(COOH)8 
is presented for the first time in this thesis. The spectroscopic characterization data 
corresponds to its structure and what has been already reported in literature for other 
octacarboxy phthalocyanines [143, 144]. The FT-IR data showed characteristic bands such as 
-OH (~3432 cm-1), -C=O (~1716 cm-1) and –CO (~1184 cm-1) which are agreement with 
what has been reported [143, 144]. The 1
Figure 4.1 shows the characteristic monomeric absorption in the Q band region at 691 nm. 
The monomeric behavior is evidenced by a single narrow Q band typical of metallated 
phthalocyanine complexes. The emission spectrum (at λ = 701 nm) was a mirror image of 
the excitation spectrum (at λ = 691 nm) and the latter was similar to the absorption 
spectrum (at λ = 691 nm) (Figure 4.1). Satisfactory NMR, mass spectra, elemental 
analysis and FT-IR data was obtained for the ClInPc(COOH)
H NMR spectra of the complex showed aromatic 
ring protons at a region between 7.82-11.56 ppm, integrating for the 8 ring protons and  8 
carboxylic acid groups protons to a total of 16 expected protons. 
8 (data not shown). Table 4.1 
shows the Q band maxima of all the Pcs used in this work. The Q band for ClInPc(COOH)8  
is more red shifted at 691 nm compared to the rest of the complexes in Table 4.1 due to the 
large In central metal atom [158]. 
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Table 4.1: The photophysical and photochemical parameters of ClGaPc(COOH)8, ClAlPc(COOH)8 
and ClInPc(COOH)8 
 
 and their conjugates in 0.1 M NaOH. 
Complex/ 
Conjugate/ 
 
 
a λ 
 
abs (Pc)
 
 
Pc:QDs 
loading 
 
a,bΦ
 
F(Pc) 
 
a,cΦ
 
F(QDs  
 
aΦ
 
T(Pc)
 aτ
F(Pc) 
(± 0.01) 
 
(ns)
 
dτ
F(QDs) 
 
(± 0.01) 
 
aτ
 
F(QDs, 
Av)
 
aτ
T(Pc)
 
(µs)
 
ClGaPc(COOH)8-
GSH-CdSe
 
(2.3 nm)# 
 
688 
(688) 
1:6 0.18 
(0.21) 
 0.23 
(0.34) 
0.63 
(0.58) 
4.3  
(3.9) 
 
31.5 (47 %) 
6.6 (21%) 
0.8 (32%) 
16.5 
(13.0) 
118 
(72) 
ClGaPc(COOH)8-
GSH-CdSe@ZnS
 
(3.0 
nm)# 
690 
(688) 
1:3 0.12 
(0.21) 
0.14 
(0.47) 
0.70 
(0.58) 
4.1  
(3.9) 
 
33.7 (53%) 
4.6 (22%) 
0.5 (25%) 
19.0 
(9.6) 
136 
(72) 
 
ClGaPc(COOH)8-
GSH-CdSe@ZnS
 
(3.5 
nm)# 
 
690 
(688) 
1:1 0.07 
(0.21) 
0.11 
(0.59) 
0.69 
(0.58) 
4.0  
(3.9) 
35.2 
(43.9%) 
6.4 (30%) 
0.3 (36.1 
%) 
17.5 
(16.8) 
134 
(72) 
ClAlPc(COOH)8-
GSH-CdSe@ZnS
 
(3.5 
nm)# 
 
689 
(689) 
1:1 0.15 
(0.23) 
0.18 
(0.59) 
0.68 
(0.53) 
3.9 
(3.7 ) 
 
36 (46.3%) 
6.9 (15%) 
0. 9 (46.8 
%) 
17.2 
(9.6) 
144 
(83) 
 
ClInPc(COOH)8-
GSH-CdSe@ZnS
 
(3.0 
nm)# 
 
693 
(691) 
1:3 0.09 
(0.13) 
0.25 
(0.47) 
0.56 
(0.49) 
3.3 
(3.4) 
29.3(29%) 
3.7(36%) 
0.4 (35%) 
18.4 
(16.8) 
169 
(67) 
a Value in brackets = Pc alone or QDs alone 
b Excitation at 665 nm  
c Excitation at 480 nm and for the conjugates, ΦF(QDs) =  𝛷𝛷𝐹𝐹(𝑄𝑄𝑄𝑄)𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐  
d 
# QDs mean diameter 
Relative abundance in brackets and excitation of QDs 
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4.1.2 QDs alone 
A different batch of QDs of different sizes were synthesized and employed in this chapter, 
this was not the same batch used in Chapter 3 and hence re-characterization of the QDs was 
necessary. Having established in Chapter 3 that GSH capped CdSe QDs with ZnS shell 
showed less toxicity, we continued the work presented in this thesis using GSH-CdSe@ZnS 
QDs, comparing with core GSH-CdSe QDs. One GSH-CdSe and two GSH-CdSe@ZnS QDs 
were synthesized.  
 
4.1.2.1 XRD 
The X-ray diffraction pattern of the core GSH-CdSe and coreshell GSH-CdSe@ZnS obtained 
is similar to Figure 3.2. The sizes for core GSH-CdSe was 2.3 nm and for the two GSH-
CdSe@ZnS QDs the sizes were 3.0 nm and 3.5 nm represented as  GSH-CdSe(2.3.nm), GSH-
CdSe@ZnS(3.0nm) and GSH-CdSe@ZnS(3.5nm)
 
 respectively, Table 4.2. 
4.1.2.2 Emission spectra 
In Figure 4.2 the core GSH-CdSe displayed an emission peak at 586 nm and after capping 
the core with ZnS the emission peak was observed at 629 nm for GSH-CdSe@ZnS(3.0nm), 681 
nm for GSH-CdSe@ZnS(3.5nm). 
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Figure 4.2: Emission spectra of core (a) GSH-CdSe (2.3 nm) core shell (b) GSH-CdSe@ZnS  
1 (3.0 nm) and (c) GSH-CdSe@ZnS 2 (3.5 nm).  Excitation wavelength = 480 nm. 
 
4.1.2.3 Microscopic data 
Transmission electron microscopy (TEM) was used to study the morphology of the core 
GSH-CdSe and the different sizes of core shell quantum dots GSH-CdSe@ZnS(3.0nm) and 
GSH-CdSe@ZnS(3.5nm). In Figure 4.3 (a) an image of core GSH-CdSe is shown, they are 
small in size estimated at 2 nm; Figure 4.3 (b) shows the increase in size upon the capping 
with the ZnS shell. The sizes are 3.3 nm and 3.6 nm for the core shell quantum dots GSH-
CdSe@ZnS(3.0nm) and GSH-CdSe@ZnS(3.5nm)
 
 which is in agreement and not too far off with 
what was obtained from the XRD patterns for GSH-CdSe@ZnS. 
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(a)                                                                   (b)                         
 
Figure 4.3: TEM images of (a) core GSH-CdSe alone (b)core shell GSH-CdSe@ZnS(3.0 nm)
 
 . 
(a)                                                                    (b) 
 
 
Figure 4.4: TEM images of:(a) GSH-CdSe@ZnS(3.5 nm) QDs alone (b) CdSe@ZnS (3.5 nm)-
ClGaPc(COOH)8   and (c) CdSe@ZnS
(3.0 nm)-ClInPc(COOH)8 
 
. 
 
 
(c) 
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Table 4.2: Sizes of various QDs used in this work, excitation wavelength 480 nm. 
QDs 
 
Pc conjugated 
to  
 
λ XRD emm 
size 
Φ τF(QDs) 
F(QDs) 
 
(± 0.01) 
τ
F(QDs), Av
 
GSH-CdSe(2.3 nm) ClGaPc(COOH)8 586 2. 3 nm 0.34 24.8 
(48%) 
6.2 (12%) 
0.9(40%) 
13.0 
GSH-CdSe 
@ZnS
 
(3.0 nm) 
ClGaPc(COOH)
 
8 
 
 
ClInPc(COOH)
629 
8 
 
 
 
634 
3.0 nm 0.47 
 
 
 
0.48 
26.9 
(31%) 
4.3 (24 
%) 
0.6(45%) 
27.9 
(24%) 
6.8 
(31%) 
0.6 
(45%) 
 
9.6 
GSH-CdSe 
@ZnS
 
(3.5 nm) 
ClAlPc(COOH)
 
8 
 
 
ClAlPc(COOH)8 
681 
 
 
 
610 
3.5 nm 0.59 
 
 
 
0.43 
27.6 
(56%) 
9.6 (13%) 
0.4 (31%) 
 
27.1 
(58%) 
6.7 
(11.3%) 
0.6 
(30.7%) 
 
 
16.8 
 
 
 
 
16.6 
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4.1.3 Characterization of conjugates of quantum dots with with Pcs 
Schemes 4.1 (A) and (B) show the formation of GSH-CdSe-ClGaPc(COOH)8 andGSH-
CdSe@ZnS-ClGaPc(COOH)8 conjugates, respectively, by linking the carboxyl group of the 
metal octacarboxy phthalocyanine to the amino group on either the GSH capped core or 
coreshell QDs.Scheme 4.1 B shows the linking of GSH-CdSe (3.5 nm) to ClInPc(COOH)8 and 
ClAlPc(COOH)8 
 
The conjugates are represented as ClGaPc(COOH)8-GSH-CdSe
(2.3 nm) for the core and 
ClGaPc(COOH)8-GSH-CdSe@ZnS
(3.0 nm) or ClGaPc(COOH)8-GSH-CdSe@ZnS
(3.5 nm) for 
the core shell conjugates of different sizes in Tables 4.2. 
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Scheme 4.1: Schematic representation of the conjugation of Pcs (ClInPc(COOH)8, ClGaPc(COOH)8 
or ClAlPc(COOH)8
 
) to either (a) GSH-CdSe or (b) GSH-CdSe@ZnS QDs. 
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In this work the number of Pcs bonded to QDs was determined following literature method as 
described in literature [159] however using absorption instead of fluorescence.  The ratios 
obtained were: GSH-CdSe: ClGaPc(COOH)8 (1:6), GSH-CdSe@ZnS
(3.0nm):ClGaPc(COOH)8 
(1:3) and GSH-CdSe@ZnS(3.5  nm):ClGaPc(COOH)8 (1:1). We observe a decrease in the 
number of Pc bonded to the QDs as the size of QDs increased. In Table 4.2 ClGaPc(COOH)8  
were coordinated to GSH-CdSe or GSH-CdSe@ZnS to check the effects of core and 
coreshells. ClGaPc(COOH)8 
 
 was also coordinated to different sizes to check the effects of 
size. 
4.1.3.1 Microscopic data 
Upon conjugating the ClGaPc(COOH)8 to the QDs aggregation was observed as seen  for the 
ClGaPc(COOH)8
(3.5 nm)-GSH-CdSe@ZnS conjugate in Figure 4.4 (b), thus making 
estimation of individual particle size impossible. The same tendency to aggregate upon 
conjugation with ClGaPc(COOH)8  was observed for all the conjugates (TEM images of the 
other two conjugates not shown). Figure 4.4 (c) shows the CdSe@ZnS(3.0 nm)-
ClInPc(COOH)8 conjugate. The particle size of the conjugate increased to 9 nm, an increase 
from QDs alone at 3.0 nm. This is probably due to the aggregation of the Pc in the presence 
of QDs also discussed above for ClGaPc(COOH)
 
8. 
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4.1.3.2 FT-IR Spectra 
FT-IR was employed to further characterize the complexes and to also confirm the formation 
of the amide bond.  With the GSH-CdSe QDs (Figure 4.5 (b) we observe a COO- stretching 
band at 1667 cm-1 and the corresponding –OH band is found at 3300 cm-1. In Figure 4.5 (c) a 
C=O vibration of the ClGaPc(COOH)8 is observed at 1653 cm
-1. Formation of characteristic 
amide bands at 1648 cm -1 and 3256 cm-1 confirm the success of the linkage Figure 4.5 (a). 
Such bands were absent for the QDs alone Figure 4.5 (b) or for the ClGaPc(COOH)8 alone 
in Figure 4.5 (a). It is known that a shift in FT-IR band confirms structural change [159], as 
was observed in this work. Similar changes were observed for all the other conjugates and for 
ClInPc(COOH)8 and  ClAlPc(COOH)8 
 
(spectra not shown). 
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Figure 4.5: FT-IR spectra of (a)ClGaPc(COOH)8-GSH-CdSe
(2.3 nm) conjugate, (b) GSH-CdSe 
(2.3 nm) and (c) ClGaPc(COOH)8
4.1.3.3 Thermogravimetric analysis (TGA) 
. 
TGA thermograms for ClInPc(COOH)8 before conjugation and after conjugation with QDs 
are shown in Figure 4.6. Curve (ii) shows that the ClInPc(COOH)8 decomposes faster than 
QDs conjugates, but is still fairly stable as it only loses 12 % of the weight percentage. 
Conjugating QDs (curve (i)) to the ClInPc(COOH)8
 
  improved the stability with the weight 
loss being 1.2 % for the Pc-QDs conjugate. The stability of the conjugates is as a result of 
thermally stable QDs. This confirms that the addition of QDs enhances the stability of the 
complex. 
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4.1.3.4 UV/vis absorption spectra of conjugates 
The absorption spectrum of ClGaPc(COOH)8   in NaOH (0.1 M), Figure 4.7 A(c) shows a Q-
band absorption at 688 nm, (Table 4.1). No change in the Q-band maximum was observed 
when core GSH-CdSe QDs were introduced Figure 4.7 A(a). The addition of QDs resulted in 
an increased absorption from around the 600 nm region, due to QDs absorption. A small 2 
nm shift of the Q band from 688 nm to 690 nm upon the introduction of the both core shell 
QDs was observed (Table 4.1). The small shift is attributed to the change in environment 
when the QDs were introduced. For ClInPc(COOH)8 and conjugates when QDs are 
introduced, the Q-band of Pc shifts from 691 nm to 693 nm, Table 4.1, Figure 4.7 B. No 
shift in Q band of ClAlPc(COOH)8 
 
 was observed when QDs were introduced.  
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4.2 Photophysical behaviour 
4.2.1 Fluorescence quantum yield (ΦF) and lifetimes (τF
The fluorescence quantum yields of the QDs increase with an increase in the size of the 
quantum dots (Table 4.2).We have reported an increase in Φ
) 
F with increase in QDs size, 
depending on the capping agent [137]. The shell is also expected to protect the core hence 
resulting in improved ΦF
When linking QDs to ClGaPc(COOH)
 values. 
8 the fluorescence quantum yield ΦF(pc) of 
ClGaPc(COOH)8 decreased from 0.21 (for Pc alone) to 0.18, 0.12 and 0.07 (for 
ClGaPc(COOH)8-GSH-CdSe and ClGaPc(COOH)8-CdSe@ZnS
(3.0nm) and ClGaPc(COOH)8-
CdSe@ZnS(3.5nm) conjugates respectively), when the excitation wavelength is where Pc 
absorbs and there is minimal absorption by the QDs (Table 4.1). The decrease in 
fluorescence quantum yield is as a result of the heavy atom effect of the QDs which enhances 
intersystem crossing (ISC) to the triplet state. For ClInPc(COOH)8  ΦF decreases from 0.13 
to 0.09 and for ClAlPc(COOH)8  from 0.23 to 0.15. The largest decrease in ΦF values when 
exciting where Pcs absorb, is observed for the larger QDs which have more heavy atoms 
hence a more enhanced ISC. The fluorescence quantum yield of QDs in the conjugate (InPc-
QDs), from ΦF = 0.48 for QDs alone to ΦF = 0.25 for the conjugate, Table 4.1. When 
excited where QDs absorb and Pcs do not, a decrease in the fluorescence quantum yields of 
the QDs  ΦF(QDs)
 
 is observed in Table 4.1. The decrease is due to FRET and other processes 
which deactivate the excited states of the QDs [160-162]. 
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The fluorescence quantum yield of the ClInPc(COOH)8  alone is low, compared to the other 
Pcs due to the enhancement of intersystem crossing by the presence of the heavier indium 
atom. Enhanced ISC results in increased triplet quantum yields as will be discussed below. 
For QDs alone, it has been reported in literature [163] that increase or decrease in ΦF
Fitting of the luminescence decay curves for the QDs and the Pc-QDs conjugates (when 
excited where QDs absorb) resulted in three lifetimes (τ
 values 
of QDs in the presence of Pcs depended on size, capping agents and hence most likely on the 
surface defects. 
F(QDs)) as is typical of QDs 
[158,159,162], Figure 4.8. For the same reason given for the ΦF values, the core shell 
showed longer lifetimes compared to core (see averaged lifetimes, Table 4.1). There is an 
increase in the average lifetimes (τF(QDs))  in the presence of the Pc. A single lifetime (τF(Pc)) 
was obtained when exciting where the Pc absorb, for all Pcs and their QDs conjugates, Table 
4.1.  There is a slight increase in τF(Pc) in the presence of QDs, except for ClInPc(COOH)8. 
 
The increase could be due to partial protection of the Pc by the QDs. 
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Figure 4.8: Fluorescence decay curve of (a) GSH-CdSe@ZnS QDs and (b)  GSH-
CdSe@ZnS QDs-ClGaPc(COOH)8
 
  conjugate in 0.1 M NaOH. 
4.2.2 Triplet Quantum yields (ΦT) and lifetimes (τT
Typical triplet decay curve for the ClGaPc(COOH)
) 
8  alone is shown in Figure 4.9 obeyed 
first order kinetics. We expect the ΦT(Pc) values of the Pcs to increase in the presence of the 
QDs as a result of the heavy atom effect which will encourage ISC, as is observed in Table 
4.1.The ΦT of the conjugates are higher than for Pcs alone. An increase in triplet lifetimes of 
Pcs in the presence of QDs is also observed in Table 4.1. We have observed the increase in 
triplet lifetimes of phthalocyanines in the presence of QDs in literature before [78]. The 
increase in the triplet lifetimes could be attributed to the protection of the Pcs by the 
nanoparticles.  
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The ΦT(Pc)  and τT(Pc) values for  ClGaPc(COOH)8-GSH-CdSe@ZnS(3.0nm)  and 
ClGaPc(COOH)8-GSH-CdSe@ZnS
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 are  similar, showing that the size of the core shell 
does not have much influence on the triplet state parameters. 
 
Figure 4.9: Triplet Decay profile of ClGaPc(COOH)8
 
 in 0.1 M NaOH. 
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Table 4.2: Forster Resonance Energy Transfer (FRET) parameters of the conjugates in 
NaOH (0.1 M). 
 
Compound J (x 10-13 R) 0 (x 10
-10 r (x 10) -10 Eff ) 
ClGaPc(COOH)8-
GSH-CdSe 
5.89 48.2 42.4 0.76 
ClGaPc(COOH)8
 
-
GSH-CdSe@ZnS  
(3.0 nm) 
6.54 44.3 40.9 0.86 
ClGaPc(COOH)8-
GSH-CdSe@ZnS 
(3.5 nm) 
6.64 43.8 41.2 0.78 
ClAlPc(COOH)8 6.34 -
GSH-CdSe@ZnS 
(3.5 nm) 
44.6 42.1 0.75 
ClInPc(COOH)8-
GSH-CdSe@ZnS 
(3.0 nm) 
6.56 45.4 41.0 0.79 
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FRET parameters were estimated from the decrease in the QDs emission and are summarized 
in Table 4.2. The J values obtained in this work were relatively high and were of the order 
10-13. For porphyrin-based complexes, J values are generally of the order of 10-14 cm6 [163], 
showing a good overlap for the conjugate in this work. The value of r was less than the values 
of R0 for the conjugates; hence the Eff values are all greater than 50% for all conjugates. As 
expected, the J values were large for the larger QDs conjugates, however we noted that 
ClGaPc(COOH)8-GSH-CdSe@ZnS
(3.0 nm) showed the highest Eff  value of 0.86. This 
corresponds to the small value of r suggesting that theClGaPc(COOH)8  is in closest 
proximity to the donor (GSH-CdSe@ZnS(3.0nm))  compared to the other conjugates and thus 
there should be an ease of energy transfer (Eff) between the excited  GSH-CdSe@ZnS(3.0nm) 
and the ClGaPc(COOH)
 
8.
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4.4 Photodynamic therapy application  
4.4.1 PDT on human carcinoid BON cells 
As proof of concept, we conjugated an aluminum octacarboxyphthalocyanine to the GSH-
CdSe@ZnS QDs and applied PDT and imaging on human pancreatic carcinoid BON cells. 
Aluminum was the choice of central metal for the octacarboxyphthalocyanine in this specific 
part of the study. This was selected as there are number aluminum pthalocyanine derivatives 
currently undergoing clinical trials [164-168], however none of those aluminum 
pthalocyanines currently in clinical trials are conjugated to QDs, hence it was the aim of this 
work. 
 
The effects of GSH-CdSe@ZnS(3.5nm)-ClAlPc(COOH)8 
In Figure 4.12 the concentration of the conjugates used were; 4 µM, 3 µM, 2 µM, 1 µM and 
0.5 µM at 10 J/cm
conjugate on the growth of human 
pancreatic carcinoid BON cells were studied by crystal violet staining as described in section 
2.4.2 [146]. One of the requirements of an excellent or an ideal photosensitizer is that it 
should not exhibit any dark toxicity, meaning it should only destroy cancerous cells when 
exposed to a light of specific wavelength. 
2
 
. No dark toxicity in the cells was observed, as made evident by the cells 
continuous growth in the medium when placed in the dark. A dosage dependant cell death 
(Figure 4.12) trend was also observed on irradiation, meaning the drugs were more efficient 
at higher concentrations, resulting in an increased cell death at higher concentration of the 
conjugate compared to the lower concentrations. At the highest concentration (4 µM) the 
conjugates were effective in killing only 36.9 % of the cells, while killing only 19.5 % at the 
lowest concentration (0.5 µM).  
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Figure 4.12: Effect of GSH-CdSe@ZnS(3.5nm)-ClAlPc(COOH)8 conjugate on the cell survival 
of BON cells 24 hours after illumination at 10 J/cm2
 
. 
 
To increase the effectiveness of the conjugates, we increased our concentration range to; 10 
µM, 5 µM, 4 µM, 2 µM and 1 µM and also increased the energy to 20 J/cm2
 
. The cells were 
monitored for 24, 48 and 72 hrs after irradiating with light. Upon increasing the energy and 
the concentration (Figure 4.13 A), it was observed after 24 hrs that at the highest 
concentration (10 µM) the conjugates were effective in killing 77.9 % of the cells, Figure 
4.13 A. 
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However, the conjugates became toxic as they also managed to kill off 80.3% of the cells in 
the dark. At the second highest concentration (5 µM) 66.5 % of the cells were killed, we still 
observed dark toxicity with 13.9% of the cells killed in the dark Figure 4.13 A, From 4 µM 
and at lower concentrations (2 µM and 1 µM) no dark toxicity was observed and 70 % of the 
cells were killed at 4 µM and 60% and 50% at 2 µM and 1 µM respectively. A dosage 
dependent trend was also observed after 24 hrs of irradiation. 
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Figure 4.13:   Effect of GSH-CdSe@ZnS(3.5nm)-ClAlPc(COOH)8 conjugation cell survival of 
BON cells at (A) 24 hrs, (B) 48 hrs and (C) 72 hours after illumination at 20 J/cm2
 
. 
After 48 hrs of illumination (Figure 4.13 B) we noted a tendency of the cells starting to re-
grow. At the highest concentration at 10 µM the cells did not grow back however the 
compounds were still toxic in the dark. At 5 µM, the second highest concentration there was 
a reduction in cell death with 32% and 40 % of the cells in the light and dark respectively. 
While at 4 µM the conjugates were effective in killing 60 % of the cells in the light and no 
dark toxicity observed, Figure 4.13 B. After 72 hrs (Figure 4.13 C) all the cells had re-
grown except at 10 µM concentration, which remains toxic. 
As seen from the above results the cancerous cells start growing back after a few days, we 
propose the following explanation; QDs by themselves are able to photo-produce free 
radicals under a high-dose irradiation, resulting in a slight cell damaging. Although a large 
 
 
                     C 
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percentage of the cells were killed, it is known that the cancerous cells multiply at faster rates 
than ordinary cells, so the few remaining cells had multiplied after a few days.  Alternatively 
the capping agent used for our QDs (GSH) is a known antioxidant which could be the result 
of cells re-growing after a few days (as it will hinder the production of the radicals 
responsible for cell death). Another possible reason could be instability of QDs in the 
medium or surface irregularities. 
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4.4.2 Fluorescence imaging 
To determine the effectiveness of our QDs in imaging applications we employed a 
fluorescence microscope, we used two different concentrations 2 µM and 4 µM. Figure 4.14 
A is the control (a) shows our cells under normal light and (b) shows the fluorescence, we do 
not expect to see any fluorescence in our control as we do not have any QDs that fluoresce. 
Figure 4.14 B and C show fluorescence images when using 2 µM and 4 µM of QDs, we are 
able to see the fluorescence and the images are much clearer at the highest concentration. The 
fluorescence property of the QDs will allow use in PDT and imaging applications.  
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(A) 
 
 
 
(B) 
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(C) 
 
Figure 4.14: Human carcinoid BON cells under normal light and under fluorescence of (A) 
control, (B) 2 µM QDs and (C) 4 µM QDs. 
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This chapter provides results on quantum dots-magnetic nanoparticles – 
phthalocyanine conjugates 
CHAPTER 5 
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5.1 Characterization of ClInPc(COOH)8
5.1.1 Uv/vis spectra  
-MNPs conjugate 
Scheme 5.1 shows the conjugation of amino functionalized Fe3O4 magnetic nanoparticles to 
ClInPc(COOH)8.  Figure 5.1 compares the absorption spectrum of (a) ClInPc(COOH)8 with 
that of (b) amino functionalized Fe3O4 magnetic nanoparticles and (c) ClInPc(COOH)8 -
Fe3O4 MNPs conjugate in 0.1 M NaOH. Amino functionalized Fe3O4 magnetic nanoparticles 
show a broad absorption at ~380 nm. ClInPc(COOH)8  absorbs at 691 nm upon introducing 
the amino functionalized Fe3O4 magnetic nanoparticles, no change in the Q-band position is 
observed and is still at 691 nm Table 5.1.  
 
Scheme 5.1: Schematic representation of the conjugation of ClInPc(COOH)8
 
 to magnetic 
nanoparticles. 
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Figure 5.1: Ground state absorption spectra of (a) ClInPc(COOH)8alone (b) amino 
functionalized Fe3O4 magnetic nanoparticles alone, (c) ClInPc(COOH)8-amino 
functionalized Fe3O4
 
 magnetic nanoparticles conjugate in 0.1 M NaOH. 
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Table 5.1: The photophysical and photochemical parameters of ClInPc(COOH)8, GSH-
CdSe@ZnS (3.5 nm) and ClInPc(COOH)8
 
-silica coated QDs-MNPs. 
 
 
Complex 
 
 
λabs(Pc) 
 
 
a ΦF(Pc) 
 
bΦF(QDs) 
 
aΦ
T(Pc)
 
 
aτ
F(Pc) 
(± 0.01) 
(ns)
 
 
cτ
F(QDs) 
(av)  
 
(ns) 
 
aτ
T(Pc) 
(µs)
 
 
ClInPc(COOH)8 
 
or QDs alone 
 
691 
 
0.13 
 
0.47 
 
0.49 
 
3.4 
 
 
8.1 
 
67 
 
ClInPc(COOH)8-
QDs-MNPs 
 
693 
 
0.06 
 
0.33 
 
 
0.66 
 
3.6 
 
 
8.9 
 
139 
ClInPc(COOH)
MNPs 
8- 
 
 
691 
 
0.10 
 
- 
 
 
0.61 
 
3.7 
 
 
- 
 
146 
ClInPc(COOH)8-
QDs 
 
693 
 
 
0.09 
 
0.25 
 
0.56 
 
3.3 
 
 
 
9.2 
 
 
168 
 
a Excitation at 665 nm and values are for excitation of the Pc.  
b Excitation at 480 nm for the QDs and conjugates (ΦF(QDs)  and (ΦF(conjugates)
 
) respectively. 
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5.1.2 FT-IR 
FT-IR was employed to further characterize the complexes and to also confirm the formation 
of the amide bond. Characteristic peaks of primary amino group  (-NH2) are observed at 1559 
cm-1 and 1482 cm-1 for the amino functionalized Fe3O4 magnetic nanoparticles, in Figure 5.2 
(i). The peak at 1034 cm-1 is assigned to Si-O-Si and Fe-O-Si bonding stretch [134], Figure 
5.2 (i). Upon conjugating MNPs to the Pc in Figure 5.2 (ii) there is an emergence of a broad 
–NH- stretch at 3283 cm-1 and the peak that is assigned to the amide group (-NHCO-) at 1631 
cm-1. This confirms successful covalent linkage of the amino functionalized Fe3O4 magnetic 
nanoparticles to the ClInPc(COOH)
 
8. 
 
 
 
 
 
 
Figure 5.2: FT-IR spectra of (i) Amino functionalized Fe3O4 magnetic nanoparticles, (ii) 
ClInPc(COOH)8-Amino functionalized Fe3O4 magnetic nanoparticles conjugate (iii) 
ClInPc(COOH)
 
8.  
 
MNPs 
Pc-
MNPs 
Pc 
114 
 
 
 
5.1.3 Microscopic data 
TEM was used to study the morphology of MNPs before and after conjugation to 
ClInPc(COOH)8. Figure 5.3 (a) show images of MNPs alone, the MNPs size was determined 
as 19 nm, spherical in nature. Upon conjugation to form ClInPc(COOH)8
 
–MNPs in Figure 
5.3 (b) the size of the conjugate increased and became aggregated making it impossible to 
measure individual particle sizes.   
 
 
 
Figure 5.3: TEM images of (a) amino functionalized Fe3O4 magnetic nanoparticles alone (b) 
ClInPc(COOH)8-amino functionalized Fe3O4 magnetic nanoparticles conjugate. 
 (a)                                                     (b) 
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5.1.5 Photophysical behavior 
5.1.5.1 Fluorescence quantum yield and lifetimes 
 
A single lifetime was obtained for both the ClInPc(COOH)8 and the ClInPc(COOH)8–MNPs 
conjugate. When linking MNPs to ClInPc(COOH)8  the fluorescence quantum yields of 
ClInPc(COOH)8 decreased from 0.13 (for Pc alone)  to 0.09 (Pc-QDs conjugate)  and 0.10 
(for Pc-MNPs conjugate) as seen in (Table 5.1). The decrease is as a result of the heavy atom 
effect of the nanoparticles. The paramagnetic nature of MNPs will also reduce the 
fluorescence quantum yields [164]. Comparing QDs with MNPs conjugates, shows only 
small differences in the ΦF
5.1.5.2 Triplet Quantum yields (Φ
 values, hence suggesting that the nature of the nanoparticle does 
not play a significant role. 
T) and lifetimes (τT
The increased Φ
) 
T(Pc) value corresponds to lower value of (ΦF(Pc)) of the ClInPc(COOH)8-
MNPs conjugate. An increase in ΦT(pc) (Table 5.1) in the presence of MNPs is attributed to 
the heavy atom effects of the MNPs as was the case with QDs in Chapter 4. The increase in 
the ΦT values was larger for ClInPc(COOH)8-MNPs compared to ClInPc(COOH)8–QDs, 
this could be related to the size of MNPs (19 nm) relative to QDs size (3.0 nm), even though 
the latter has heavier atoms. The defects on the nanoparticles will also affect their properties. 
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The increase in ΦT is advantageous as it means the combining QDs and MNPs with 
phthalocyanines will increase the triplet state population of the phthalocyanine, therefore 
resulting in higher photosensitizing ability [169]. Triplet lifetimes increased for 
ClInPc(COOH)8
Increase in the triplet yields and lifetimes for Pcs in the presence of QDs [76,77] and other 
nanoparticles [170] has been documented before. The increase in the triplet lifetimes could be 
attributed to the protection of the Pcs by the nanoparticles, as stated in section 4.2.2. The 
longer triplet lifetime for ClInPc(COOH)
 in the presence of QDs or MNPs.  It was previously reported in literature 
that conjugating MNPs to ZnPc increased the triplet lifetime [99].  
8–QDs  corresponds to the smaller ΦT
 
 value. 
5.1.5.3 General conclusions 
Conjugates of Fe3O4 magnetic nanoparticles (MNPs) with indium octacarboxy 
phthalocyanine (ClInPc(COOH)8) showed a decrease in the fluorescence lifetimes of 
InPc(COOH)8 due to MNPs. The triplet quantum yields increased from ΦT = 0.49 for 
InPc(COOH)8 alone to ΦT 
 
= 0.61 for Pc-MNPs. The lifetimes also became longer for the 
conjugates compared to Pc alone. Both conjugates were extremely thermally stable. The fact 
both the triplet yields and lifetimes increase suggest that these conjugates are suitable 
candidates for PDT and as bi-functional anticancer agents for cancer treatment and thermal 
stability will also be suitable in hyperthermia applications.  
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5.2 Investigating photophysical properties of multi-functional quantum dots-magnetic 
nanoparticles–indium octacarboxyphthalocyanine nanocomposite 
This part of the work presents the development of a possible multifunctional hybrid 
nanoparticle made of L-glutathione capped quantum dots (GSH-CdSe@ZnS
(3.5nm)), amino 
functionalized Fe3O4 magnetic nanoparticles and indium octacarboxyphthalocyanine 
(ClInPc(COOH)8
 
). We investigate the photophysical properties of the individual components 
and the hybrid nanoparticle, in addition we study the energy transfer (Förster Resonance 
Energy Transfer (FRET)) in the complex. GSH-CdSe@ZnS QDs of size 3.5 nm was 
employed. 
Scheme 5.2 shows the schematic representation of the covalent linkage of the 
(ClInPc(COOH)8  (Pc) to the silica coated QDs-MNPs. The QDs were first conjugated to 
MNPs as described in section 2.3.5, the resulting complex was coated with silica as described 
in literature [145], by simultaneous sol-gel polymerization of tetraethoxysilane (TEOS). 
ClInPc(COOH)8 was attached on the surface of the silica coated-QDs-MNPs conjugate by 
taking advantage of the –NH2 groups and using them as points of attachment. The 
multifunctional nanocomposite is represented as ClInPc(COOH)8-QDs-MNPs. 
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Scheme 5.2: Schematic representation of the covalent linkage of the (ClInPc(COOH)8
 
  (Pc) 
to the silica coated QDs-MNPs. 
 
 
 
5.2.1 Characterization of the nanocomposites 
5.2.1.1 UV-Vis spectra 
Figure 5.5 shows the UV-Vis spectra of the (a) amino functionalized Fe3O4 magnetic 
nanoparticles, (b) GSH-CdSe@ZnS QDs and (c) the silica coated QDs-MNPs conjugate. The 
amino functionalized Fe3O4 magnetic nanoparticles show a broad absorption at ~385 nm 
which is typical of magnetic nanoparticles. Upon conjugating the two (QDs and MNPs) an 
enhanced absorption is noted in the regions where the two absorb. 
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Figure 5.5:  Ground state absorption spectra of (a) amino functionalized Fe3O4
 
 magnetic 
nanoparticles (MNPs) (b) GSH-CdSe@ZnS (QDs) and (c) silica coated QDs-MNPs complex 
Figure 5.6 compares the ground state absorption spectra of ClInPc(COOH)8 and  
ClInPc(COOH)8-QDs-MNPs. Upon conjugation there is slight shift in the Q-band maxima, a 
3 nm shift from 691 nm (Pc alone) to 693 nm (conjugate), Table 5.1 there is also an 
enhanced absorption below 600 nm region due to the absorption of QDs and MNPs. This 
indicates successful linkage of the ClInPc(COOH)8 to the silica coated QDs-MNPs complex. 
There were also no significant Q band shifts for ClInPc(COOH)8 in the presence of QDs or 
MNPs alone, Table 5.1. 
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Figure 5.6: Ground state absorption spectra of (a) ClInPc(COOH)8  and (b) ClInPc(COOH)8 
 
-silica coated QDs-MNPs complex 
5.2.1.2 TEM images 
Using TEM, the size of MNPs was determined as 22 nm and they were spherical in nature as 
seen in Figure 5.7. TEM images of QDs-MNPs the particles showed aggregation making the 
determination of the individual particle size impossible, Figure 5.7c. The aggregation of the 
ClInPc(COOH)8-QDs-MNPs conjugate is seen in Figure 5.7d, hence we were unable to 
determine individual particle sizes using TEM. Using XRD the sizes of the QDs-MNPs-Pc 
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conjugate was determined to be 82 nm which is not very different from what has been 
observed in literature for silica coated Fe3O4
 
-QDs conjugates reported to be ~100 nm[171]. 
Figure 5.7: TEM images of (a) GSH-CdSe@ZnS (QDs), (b) amino functionalized Fe3O4 
magnetic nanoparticles (MNPs), (c) silica coated QDs-MNPs conjugate and (d) 
ClInPc(COOH)8
 
-QDs-MNPs conjugate. 
5.2.1.3 FTIR Spectra 
In Figure 5.8 A (a) for the QDs we observe a COO- stretching band at 1591 cm-1 and the 
corresponding –OH band is found around the 3400 cm-1 region. Characteristic peaks of 
primary amino group  (-NH2) are observed at 1559 cm
-1 and 1550 cm-1 for the amino 
functionalized Fe3O4 magnetic nanoparticles, in Figure 5.8 A (b). The peak at 1034 cm
-1 is 
assigned to Si-O-Si and Fe-O-Si bonding stretch [134]. Successful chemical linkage of MNPs 
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to QDs is confirmed by in Figure 5.8 A (c), as is judged by the formation of bands 
corresponding to primary and secondary amide at 1738 cm-1 and 1481 cm -1, the 
encapsulation with the silica was confirmed by the band at 1135 cm -1 which is attributed to 
the Si-O peak. In Figure 5.8 B we compare the FT-IR of; (a) ClInPc(COOH)8, (b) silica 
coated QD-MNPs conjugate  and (c) ClInPc(COOH)8-silica coated QDs-MNPs conjugate. In 
Figure 5.8 B (a) for ClInPc(COOH)8   the  C=O vibration of the ClInPc(COOH)8 is observed 
at 1664 cm-1, a broad peak near 3250 cm-1 corresponds to O-H of the carboxyl groups. The 
latter broadens upon conjugation with the silica coated QDs-MNPs complex, (Figure 5.8 
B(c)). A peak at 1653 cm-1 corresponds to the amide bond and confirms the success of the 
conjugation. The peaks at 971 and 1091 cm-1
 
 are attributed to the presence of silica (Figure 
5.8 B(c)). 
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Figure 5.8: FT-IR spectra of: (A) (a) GSH-CdSe@ZnS QDs, (b) Amino functionalized 
Fe3O4 magnetic nanoparticles (MNPs) and (c) silica coated QDs-MNPs, (B) (a) 
ClInPc(COOH)8, (b) silica coated QDs-MNPs and (c) ClInPc(COOH)8
 
silica coated QDs-
MNPs. 
 
 
 
5.2.2 Photophysical parameters 
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5.2.2.1 Fluorescence quantum yields 
When linking the silica coated QDs-MNPs complex to ClInPc(COOH)8 we observed a 
decrease in the fluorescence quantum yield (Φ𝐹𝐹(𝑃𝑃𝑐𝑐))of ClInPc(COOH)8  (when exciting 
where Pc absorbs and there is minimal absorption by the QDs). The fluorescence quantum 
yield decreased from 0.13 (for Pc alone) to 0.06 (ClInPc(COOH)8-QDs-MNPs  conjugate) 
(Table 5.1). The decrease is as a result of the heavy atom effect of the nanoparticles (QDs 
and MNPs). The paramagnetic nature of MNPs has also been reported to reduce the 
fluorescence quantum yields. There is also a decrease in fluorescence (Φ𝐹𝐹(𝑃𝑃𝑐𝑐))  for 
ClInPc(COOH)8 when linked individually to MNPs or QDs, Table 5.1, as discussed 
already.We also excited where QDs absorb and Pcs do not. We observed a decrease in the 
fluorescence quantum yield of QDs in the conjugate (ClInPc(COOH)8-QDs-MNPs), from 
Φ𝐹𝐹(𝑄𝑄𝑄𝑄𝑄𝑄)= 0.47 for QDs alone to Φ𝐹𝐹(𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐 ) = 0.33 for the conjugate (Table 5.1). FRET 
and other processes which deactivate the excited states of the QDs have been reported to 
decrease the fluorescence quantum yield [162]. Interestingly when QDs alone are linked to 
ClInPc(COOH)8
 
, without MNPs, there is a larger quenching of their fluorescence, Table 5.1, 
suggesting that the presence of MNPs reduces the surface defects of QDs which result in 
reduced fluorescence. 
5.2.2.2 Triplet Quantum yields (ΦT) and lifetimes (τT
 The Φ
) 
T of the ClInPc(COOH)8-QDs-MNPs conjugate  (ΦT =0.66)  was higher than for 
ClInPc(COOH)8 alone  at ΦT  = 0.49, Table 5.1. An increase in ΦT in the presence of QDs 
and MNPs is attributed to the combined heavy atom effect of the MNPs and QDs, thus 
encouraging ISC. The increase in ΦT suggests that 3-in one complex (ClInPc(COOH)8-QDs-
127 
 
MNPs) will increase the triplet state population of the phthalocyanine, therefore resulting in 
enhanced photosensitizing ability. The triplet state quantum yields and lifetimes for 
ClInPc(COOH)8 increased in all cases in the presence of MNPs, QDs or QDs-MNPs. The 
largest increase in triplet lifetimes is observed for conjugate of QDs alone, Table 5.1. The 
increase triplet lifetimes suggest that the MNPs, QDs or QDs-MNPs protect the 
ClInPc(COOH)8 
 
against the environment.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
5.2.3 Förster Resonance energy Transfer (FRET) studies 
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We also investigated energy transfer between the silica coated QDs-MNPs conjugate and the 
Pc, (Figure 5.9) 
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Figure 5.9: Fluorescence emission spectra of (a) GSH-CdSe@ZnS QDs alone (b) 
ClInPc(COOH)8
 
-QDs-MNPs conjugate. 
FRET occurrence is made evident by the decrease in the photoemission of the donor 
accompanied by an increase in the acceptors fluorescence. For the ClInPc(COOH)8-QDs-
MNPs conjugate, excitation was carried at 520 nm where QDs absorb but the phthalocyanine 
does not absorb. A stimulated emission peak was observed where the Pc emits at around 698 
nm, which suggests a transfer of energy from the QDs to ClInPc(COOH)8 
 
(Figure 5.9). 
As stated above, there are other processes which deactivate the excited states of the QDs in 
addition to FRET, hence a weak stimulated emission peak is observed in Figure 5.9, and the 
calculated FRET efficiencies (Eff) are estimates. The Eff values was found to be 0.79 for 
 
Stimulated emission 
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ClInPc(COOH)8-QDs-MNPs corresponding to R0 (63.3Å) being greater that r (47.8Å).  For 
ClInPc(COOH)8-QDs alone, the Eff  values was found to be 0.79 corresponding to R0 
(45.4Å) being greater than r (41.0Å).  The J values obtained in this work were 6.56 x 10-14 
cm6 for both the ClInPc(COOH)8-QDs alone and  for ClInPc(COOH)8
 
-QDs-MNPs. Thus the 
value is not different from when QDs alone without MNPs.  
5.4.3 General conclusions 
The multi-functional nanocomposite showed improved photophysical properties and we were 
able to demonstrate a transfer of energy in the complex. FRET efficiencies of ~ 79 % were 
obtained for energy transfer between the QDs (when alone or linked to MNPs and Pc). Both 
quantum triplet yields and lifetimes of ClInPc(COOH)8 
 
increase in the nanocomposite, with a 
decrease in fluorescence lifetime. These improved photophysical parameters makes this 3-in-
one complex a suitable candidate as a multifunctional drug in PDT applications. 
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Thesis Conclusion 
CHAPTER 6 
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6.1 Thesis Conclusions  
Of the seven different types of quantum dots without shell (L-cysteine-CdTe, TGA-CdTe, 
MPA-CdTe, TGA-CdSe) and with the shell (GSH-CdSe@ZnS, GSH-CdTe@ZnS) screened, 
GSH-CdSe@ZnS was determined as the least toxic of the batch.  The GSH-CdSe@ZnS QDs 
displayed the lowest growth inhibitory potential and no embryotoxicity. GSH-CdSe@ZnS 
QDs were chemically coordinated to ClAlPc(COOH)8, ClGaPc(COOH)8 and 
ClInPc(COOH)8. Characterization techniques, including UV/Vis, FT-IR, XRD and TEM 
confirmed successful coordination of the various Pcs to the QDs, while TGA showed 
improved thermal stability of the conjugates. The conjugates showed improved photophysical 
properties. Amino functionalized magnetic nanoparticles (Fe3O4) were also conjugated to 
indium octacarboxy phthalocyanine. The conjugate enhanced the photophysical behaviour 
and as a result could be used as a potential bi-functional anti-cancer agent (hyperthermia and 
photodynamic therapy applications). The three-in-one multifunctional nanocomposite 
developed showed great photophysical behaviour. Finally the application of GSH-
CdSe@ZnS- ClAlPc(COOH)8
6.2 Future work 
 showed a dosage dependant cell death. 
To test the effectiveness of the newly synthesized multifunctional nanocomposite in vivo and 
in vitro.  Synthesize a new batch of quantum dots employing two shells that will protect the  
core from leaching and employ different capping agents such as L-cystiene  and evaluate the 
toxicity of the new QDs. Further conjugate the new QDs to Pcs with various central metals 
and apply the conjugates in Photodynamic therapy applications.   
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